

Nivolumab plus Ipilimumab in Advanced Non-“Small

New England Journal of Medicine

381, 2020-2031

DOI: [10.1056/nejmoa1910231](https://doi.org/10.1056/nejmoa1910231)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed. <i>Cancers</i> , 2019, 11, 1782.	1.7	53
2	A first attempt to establish a definition of oligometastatic non-small cell lung cancer by a European consensus group. <i>Journal of Thoracic Disease</i> , 2019, 11, 5635-5642.	0.6	0
3	Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1798.	1.7	99
5	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. , 2019, 7, 316.		102
6	Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?. <i>Drugs</i> , 2019, 79, 1937-1945.	4.9	4
7	From trends to transformation: where cardio-oncology is to make a difference. <i>European Heart Journal</i> , 2019, 40, 3898-3900.	1.0	40
8	One or Two Immune Checkpoint Inhibitors?. <i>Cancer Cell</i> , 2019, 36, 579-581.	7.7	11
9	Approach to stage IV non-small-cell lung cancer. <i>Current Opinion in Pulmonary Medicine</i> , 2019, Publish Ahead of Print, 311-320.	1.2	1
10	Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. <i>Journal of Thoracic Oncology</i> , 2020, 15, 426-435.	0.5	181
11	Efficacy of PD-1 blockade therapy and T cell immunity in lung cancer patients. <i>Immunological Medicine</i> , 2020, 43, 10-15.	1.4	3
12	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 499-519.	0.5	203
13	Twenty-five years of <i>Respirology</i> : Advances in lung cancer. <i>Respirology</i> , 2020, 25, 26-31.	1.3	2
14	Frontline immunotherapy for NSCLC – the tale of the tail. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 73-74.	12.5	35
15	Immune checkpoint blockade and biomarkers of clinical response in non-small cell lung cancer. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12980.	1.3	14
16	To Continue or Not to Continue? That Is the Question. <i>Journal of Clinical Oncology</i> , 2020, 38, 3830-3832.	0.8	2
17	Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study. <i>Frontiers in Immunology</i> , 2020, 11, 2048.	2.2	58
18	Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Cancers</i> , 2020, 12, 2831.	1.7	12
19	Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2020, 12, 1313-1324.	1.0	5

#	ARTICLE	IF	CITATIONS
20	Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1649.	1.3	32
21	Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors. <i>AAPS Journal</i> , 2020, 22, 132.	2.2	27
22	From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy. <i>Cancers</i> , 2020, 12, 2974.	1.7	18
23	Targeting STAT3 in Cancer Immunotherapy. <i>Molecular Cancer</i> , 2020, 19, 145.	7.9	423
24	Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC. <i>Immunotherapy</i> , 2020, 12, 1067-1075.	1.0	15
25	First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions. <i>Drugs</i> , 2020, 80, 1783-1797.	4.9	12
26	The PD-1/PD-L1-Checkpoint Restrains T Cell Immunity in Tumor-Draining Lymph Nodes. <i>Cancer Cell</i> , 2020, 38, 685-700.e8.	7.7	299
27	Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context. <i>European Journal of Cancer</i> , 2020, 140, 76-85.	1.3	30
28	Immune Checkpoint Inhibitor Therapy Aggravates T Cell-Driven Plaque Inflammation in Atherosclerosis. <i>JACC: CardioOncology</i> , 2020, 2, 599-610.	1.7	69
29	Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective. <i>Chinese Medical Journal</i> , 2020, 133, 2466-2475.	0.9	4
30	Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives. <i>Biomarkers in Medicine</i> , 2020, 14, 1383-1392.	0.6	16
31	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101580.	1.9	22
32	The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients. <i>Medicine (United States)</i> , 2020, 99, e22555.	0.4	2
33	Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer. <i>Chinese Medical Journal</i> , 2020, 133, 2444-2455.	0.9	7
34	Expression and Clinical Significance of CMTM6 in Nonsmall Cell Lung Cancer. <i>DNA and Cell Biology</i> , 2020, 39, 2265-2271.	0.9	9
35	Impact of anatomic site on antigen-presenting cells in cancer. , 2020, 8, e001204.		10
36	Rapid and Complete Response to Combination Anti-CTLA-4 and Anti-PD-1 Checkpoint Inhibitor Therapy in a Patient With Stage IV Refractory End-stage Epithelioid Sarcoma: A Case Report. <i>Journal of Immunotherapy</i> , 2020, 43, 286-290.	1.2	17
37	Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1. <i>Frontiers in Oncology</i> , 2020, 10, 549198.	1.3	2

#	ARTICLE	IF	CITATIONS
39	Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung Cancer. <i>Cell</i> , 2020, 183, 303-304.	13.5	4
40	Assessment of long non-coding RNA expression reveals novel mediators of the lung tumour immune response. <i>Scientific Reports</i> , 2020, 10, 16945.	1.6	16
41	The Resistance Mechanisms of Lung Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 568059.	1.3	47
42	Higher Checkpoint Inhibitor Arthritis Disease Activity may be Associated With Cancer Progression: Results From an Observational Registry. <i>ACR Open Rheumatology</i> , 2020, 2, 595-604.	0.9	13
43	Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer. <i>Cancer Medicine</i> , 2020, 9, 8406-8411.	1.3	31
46	Prise en charge des mÃ©tastases osseuses des cancers broncho-pulmonaires non Ã petites cellules. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, 2S223-2S232.	0.0	0
47	La prise en charge des mÃ©tastases cÃ©rÃ©brales du cancer bronchique. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, 2S233-2S242.	0.0	0
48	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2020, 31, 1491-1505.	0.6	658
49	Emerging role of immune checkpoint inhibitors and predictive biomarkers in head and neck cancers. <i>Oral Oncology</i> , 2020, 109, 104977.	0.8	10
50	Immune escape: A critical hallmark in solid tumors. <i>Life Sciences</i> , 2020, 258, 118110.	2.0	91
51	Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. <i>Cancers</i> , 2020, 12, 1905.	1.7	14
52	Circular RNA circ-LDLRAD3 serves as an oncogene to promote non-small cell lung cancer progression by upregulating SLC1A5 through sponging miR-137. <i>RNA Biology</i> , 2020, 17, 1811-1822.	1.5	28
53	Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors. <i>Medicine (United States)</i> , 2020, 99, e21273.	0.4	9
54	Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. , 2020, 8, e000648.		15
55	Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093790.	1.4	49
56	Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. <i>Translational Lung Cancer Research</i> , 2020, 9, 617-628.	1.3	8
57	Immune Checkpoint Inhibitors for Patients Agedâ€‰â‰¥â€‰75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis. <i>Drugs and Aging</i> , 2020, 37, 747-754.	1.3	24
58	Efficacy and safety of immune checkpoint inhibitors in patients with advanced nonâ€‰small cell lung cancer (NSCLC): a systematic literature review. <i>Oncolmmunology</i> , 2020, 9, 1774314.	2.1	34

#	ARTICLE	IF	CITATIONS
60	Novel systemic therapy for hepatocellular carcinoma. <i>Hepatology International</i> , 2020, 14, 638-651.	1.9	15
61	Association between tumor mutation burden and immune infiltration in ovarian cancer. <i>International Immunopharmacology</i> , 2020, 89, 107126.	1.7	26
62	Radiotherapy for unresectable locally advanced non-small cell lung cancer: a narrative review of the current landscape and future prospects in the era of immunotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2097-2112.	1.3	5
63	Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 584423.	2.2	39
64	Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis. <i>Journal of Translational Medicine</i> , 2020, 18, 446.	1.8	1
65	Emerging immune checkpoint inhibitors for the treatment of head and neck cancers. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 501-514.	1.0	7
66	New insights into the interaction of the immune system with non-small cell lung carcinomas. <i>Translational Lung Cancer Research</i> , 2020, 9, 2199-2213.	1.3	11
67	Genomic Characterization of NSCLC in African Americans: A Step Toward "Race-Aware" Precision Medicine. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1800-1802.	0.5	2
68	A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy. <i>Scientific Reports</i> , 2020, 10, 20575.	1.6	10
69	Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients. <i>Medical Oncology</i> , 2020, 37, 111.	1.2	13
70	Imperfect Predictors for Lung Cancer Immunotherapy – A Field for Further Research. <i>Frontiers in Oncology</i> , 2020, 10, 568174.	1.3	14
71	Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). <i>BMC Cancer</i> , 2020, 20, 1185.	1.1	75
72	Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer. <i>Cancers</i> , 2020, 12, 3625.	1.7	27
73	Première ligne des CBNPC avancés sans addiction oncogénique : quel traitement pour quel patient ? <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, 2S329-2S338.	0.0	0
74	Tolérance de l'immunothérapie en combinaison dans le cancer bronchique non à petites cellules. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, 2S344-2S351.	0.0	0
75	SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. , 2020, 8, e000705.		20
76	First line Immunotherapy for Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2020, 13, 373.	1.7	49
78	First-line immune-chemotherapy combination for squamous NSCLC is already a reality. <i>Translational Lung Cancer Research</i> , 2020, 9, 819-823.	1.3	1

#	ARTICLE	IF	CITATIONS
79	The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No. <i>Annals of Oncology</i> , 2020, 31, 1112-1114.	0.6	68
80	The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2020, 87, 106852.	1.7	3
81	Treatment of muscle-invasive and advanced bladder cancer in 2020. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 404-423.	157.7	507
82	Emerging Therapies in Thoracic Malignancies—Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non-Small Cell Lung Cancer. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 555-569.	0.6	6
83	NATURAL COMPOUNDS FROM DJIBOUTIAN MEDICINAL PLANTS AS INHIBITORS OF COVID-19 BY IN SILICO INVESTIGATIONS. <i>International Journal of Current Pharmaceutical Research</i> , 0, , 52-57.	0.2	5
84	Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data. <i>Cancer Treatment Reviews</i> , 2020, 89, 102085.	3.4	41
85	Identification of Prognostic Immune-Related Genes by Integrating mRNA Expression and Methylation in Lung Adenocarcinoma. <i>International Journal of Genomics</i> , 2020, 2020, 1-20.	0.8	11
86	Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper. <i>British Journal of Cancer</i> , 2020, 123, 874-884.	2.9	15
87	Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?. <i>Frontiers in Oncology</i> , 2020, 10, 1193.	1.3	13
88	Understanding Response to Immunotherapy Using Standard of Care and Experimental Imaging Approaches. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 242-257.	0.4	8
89	Precision medicine in non-small cell lung cancer: Current applications and future directions. <i>Seminars in Cancer Biology</i> , 2022, 84, 184-198.	4.3	106
90	Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2020, 21, 69.	1.3	20
91	Are Immune Checkpoint Inhibitors Effective Against Uncommon Oncogene-Driven NSCLC Subtypes?. <i>Journal of Thoracic Oncology</i> , 2020, 15, 489-492.	0.5	1
92	Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Pharmacology</i> , 2021, 106, 123-136.	0.9	24
93	Failure Mode and Effects Analysis (FMEA) for Immunogenicity of Therapeutic Proteins. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 3214-3222.	1.6	2
94	Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6885-6896.	1.0	1
95	Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver. <i>Lung Cancer Management</i> , 2020, 9, LMT36.	1.5	19
96	Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma. <i>Vaccines</i> , 2020, 8, 447.	2.1	19

#	ARTICLE	IF	CITATIONS
97	The adverse events associated with combination immunotherapy in cancers: Challenges and chances. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e154-e159.	0.7	11
98	Immune Oncology Biomarkers in Lung Cancer: an Overview. <i>Current Oncology Reports</i> , 2020, 22, 107.	1.8	8
99	First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress. <i>Frontiers in Pharmacology</i> , 2020, 11, 578091.	1.6	51
100	Immunotherapy and Coronavirus Disease 2019: Challenges and Possibilities. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1709-1710.	0.5	1
101	Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma. <i>Journal of Bone Oncology</i> , 2020, 25, 100332.	1.0	19
102	Case of anti-Zic4 antibody-mediated cerebellar toxicity induced by dual checkpoint inhibition in head and neck squamous cell carcinoma. <i>BMJ Case Reports</i> , 2020, 13, e235607.	0.2	9
103	Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12.	0.9	16
104	<p>Immunotherapeutic and Targeted Approaches in Multiple Myeloma</p>. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 201-215.	2.7	14
105	Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Nonâ€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 1952.	3.4	241
106	Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. <i>Biomarker Research</i> , 2020, 8, 35.	2.8	122
107	Efficacy of immuneâ€“checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and metaâ€“analysis. <i>Cancer Medicine</i> , 2020, 9, 7613-7625.	1.3	12
108	Challenges associated with systemic therapy for older patients with inoperable non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2185-2194.	0.9	1
109	Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapyâ€“naïve advanced melanoma. <i>Journal of Dermatology</i> , 2020, 47, 1257-1266.	0.6	16
110	Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review. <i>PLoS ONE</i> , 2020, 15, e0238536.	1.1	34
111	Promising predictors of checkpoint inhibitor response in NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 931-937.	1.1	15
112	Antibody-Mediated Inhibition of CTLA4 Aggravates Atherosclerotic Plaque Inflammation and Progression in Hyperlipidemic Mice. <i>Cells</i> , 2020, 9, 1987.	1.8	43
113	Tracking the tail. , 2020, 8, e000971.		3
114	A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians. <i>Translational Lung Cancer Research</i> , 2020, 9, 1124-1137.	1.3	6

#	ARTICLE	IF	CITATIONS
115	Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab. <i>Translational Lung Cancer Research</i> , 2020, 9, 1533-1542.	1.3	43
116	Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1671.	1.3	25
117	Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188420.	3.3	34
118	Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. <i>Cancer Cell</i> , 2020, 38, 489-499.e3.	7.7	216
119	Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy. <i>Lung Cancer</i> , 2020, 148, 159-165.	0.9	17
120	Brain metastases: lessons and challenges in the targeted therapy and immunotherapy era. <i>Journal of Thoracic Disease</i> , 2020, 12, 4527-4530.	0.6	3
121	Cancer patient stratification based on the tumor microenvironment. <i>Journal of Thoracic Disease</i> , 2020, 12, 4522-4526.	0.6	5
122	Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. <i>British Journal of Ophthalmology</i> , 2021, 105, 1263-1271.	2.1	36
123	New technology on the horizon: Fast analytical screening technique FNA (FASTâ€FNA) enables rapid, multiplex biomarker analysis in head and neck cancers. <i>Cancer Cytopathology</i> , 2020, 128, 782-791.	1.4	6
124	Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC). <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 149.	3.5	208
125	An update on the immune landscape in lung and head and neck cancers. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 505-517.	157.7	93
126	Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 1563.	3.4	198
127	Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced nonâ€small cell lung cancer without tumor PDâ€L1 expression: A pooled analysis of 3 randomized controlled trials. <i>Cancer</i> , 2020, 126, 4867-4877.	2.0	69
128	Improving human cancer therapy through the evaluation of pet dogs. <i>Nature Reviews Cancer</i> , 2020, 20, 727-742.	12.8	102
129	Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. , 2020, 8, e001282.		108
130	Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11271-11285.	2.9	45
131	ctDNA Concentration, MIK167 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC. <i>Frontiers in Oncology</i> , 2020, 10, 1706.	1.3	17
132	Ipilimumab-Induced Enterocolitis: A Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2020, 43, 1255-1266.	1.4	5

#	ARTICLE	IF	CITATIONS
133	Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2495.	1.7	12
134	Combined Methylome and Transcriptome Analyses Reveals Potential Therapeutic Targets for EGFR Wild Type Lung Cancers with Low PD-L1 Expression. <i>Cancers</i> , 2020, 12, 2496.	1.7	11
135	Immunotherapy in Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 2522.	1.7	60
136	Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook. <i>Molecular Cancer</i> , 2020, 19, 141.	7.9	141
137	Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy. <i>Pharmaceutics</i> , 2020, 12, 758.	2.0	6
138	Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy. <i>Current Oncology Reports</i> , 2020, 22, 109.	1.8	10
139	Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1329-1338.	1.0	64
140	<p>Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7229-7241.	1.0	12
141	C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study. <i>Cancers</i> , 2020, 12, 2319.	1.7	52
142	Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 601497.	2.2	21
143	Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 602762.	1.3	59
144	Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy. <i>Biomedicines</i> , 2020, 8, 617.	1.4	14
145	Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota. <i>Frontiers in Immunology</i> , 2020, 11, 600886.	2.2	43
146	Establishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients. <i>Cancers</i> , 2020, 12, 3846.	1.7	5
147	Applicability of the PACIFIC trial results in patients not eligible for the PACIFIC trial: Canadian rapid consensus statement and recommendations.. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100265.	0.7	3
148	LINC00857 Interacting with YBX1 to Regulate Apoptosis and Autophagy via MET and Phosphor-AMPKa Signaling. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 22, 1164-1175.	2.3	32
149	Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a "Real-Life" Setting. <i>Cancers</i> , 2020, 12, 3707.	1.7	12
150	Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy. <i>Cancers</i> , 2020, 12, 3729.	1.7	55

#	ARTICLE	IF	CITATIONS
151	Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with ALK Rearrangement-Positive Large Cell Neuroendocrine Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9705.	1.8	12
152	What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 485-495.	1.0	5
153	Immune Modulation in Lung Cancer: Current Concepts and Future Strategies. <i>Respiration</i> , 2020, 99, 903-929.	1.2	18
154	Changing paradigm in advanced and metastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 6992-7001.	0.6	3
155	A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS $\geq 1\%$ Metastatic NSCLC. <i>Cancers</i> , 2020, 12, 3648.	1.7	14
156	Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 517-524.	1.0	18
157	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2020, 12, CD013257.	1.5	30
158	The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?. <i>Frontiers in Immunology</i> , 2020, 11, 574271.	2.2	112
159	Präzisionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten. <i>Karger Kompass Pneumologie</i> , 2020, 8, 300-317.	0.0	1
160	Current status, challenges and perspectives: immunotherapy and tumour microenvironment in thoracic cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 4496-4497.	0.6	0
161	Biomarkers in immunotherapy: literature review and future directions. <i>Journal of Thoracic Disease</i> , 2020, 12, 5119-5127.	0.6	7
162	New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2020, 9, 3543.	1.0	28
163	Update 2020: Management of Non-Small Cell Lung Cancer. <i>Lung</i> , 2020, 198, 897-907.	1.4	270
164	Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2020, 3, e2017675.	2.8	20
165	Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?. <i>BioDrugs</i> , 2020, 34, 749-762.	2.2	5
166	Future of immune checkpoint inhibitors: focus on tumor immune microenvironment. <i>Annals of Translational Medicine</i> , 2020, 8, 1095-1095.	0.7	27
167	The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. <i>Vaccines</i> , 2020, 8, 203.	2.1	38
168	Ongoing challenges of using immunotherapy in special populations: Poor performance status patients, elderly patients, and people living with HIV. <i>Lung Cancer</i> , 2020, 145, 71-75.	0.9	10

#	ARTICLE	IF	CITATIONS
169	Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2020, 9, 401-405.	1.3	1
170	New first-line treatment strategies for advanced lung squamous cell carcinoma. <i>Translational Lung Cancer Research</i> , 2020, 9, 414-417.	1.3	0
171	Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic. <i>Frontiers in Oncology</i> , 2020, 10, 862.	1.3	27
172	The Effects of Obesity on Anti-Cancer Immunity and Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 1230.	1.7	74
173	Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy-free, first-line treatment for PD-L1-positive non-small cell lung cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, 107-115.	1.7	26
174	Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. <i>Cancers</i> , 2020, 12, 1125.	1.7	43
175	Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment. <i>International Journal of Cancer</i> , 2020, 147, 2658-2668.	2.3	13
176	Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 480.	1.3	28
177	Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 1362.	1.0	102
178	Keynote 42: Pembrolizumab, PD-L1, and where to draw the line. <i>Annals of Translational Medicine</i> , 2020, 8, 517-517.	0.7	2
179	Mechanistic Learning for Combinatorial Strategies With Immuno-oncology Drugs: Can Model-Informed Designs Help Investigators?. <i>JCO Precision Oncology</i> , 2020, 4, 486-491.	1.5	9
180	Different interpretations of the CheckMate-227 trial in non-small-cell lung cancer. <i>Contemporary Clinical Trials Communications</i> , 2020, 18, 100578.	0.5	1
181	Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer—Reply. <i>JAMA Oncology</i> , 2020, 6, 1116.	3.4	0
182	Assessment of associations between clinical and immune microenvironmental factors and tumor mutation burden in resected nonsmall cell lung cancer by applying machine learning to whole-slide images. <i>Cancer Medicine</i> , 2020, 9, 4864-4875.	1.3	14
183	The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 775-783.	1.0	2
184	Reintroduction of nivolumab in a patient with gastric cancer after improvement of nivolumab-induced acute interstitial nephritis: a case report. <i>International Cancer Conference Journal</i> , 2020, 9, 127-132.	0.2	3
185	Principles of Immunotherapy in Non-Small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2020, 30, 187-198.	0.4	19
186	Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer. <i>Cancer Discovery</i> , 2020, 10, 1330-1351.	7.7	424

#	ARTICLE	IF	CITATIONS
187	Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3816.	1.8	17
188	Immunotherapy for platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 158, 484-488.	0.6	40
189	RAS-targeted therapies: is the undruggable drugged?. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 533-552.	21.5	569
190	Bioinformatics analysis of the circRNA-miRNA-mRNA network for non-small cell lung cancer. <i>Journal of International Medical Research</i> , 2020, 48, 030006052092916.	0.4	31
191	Intestinal microbiota: a new force in cancer immunotherapy. <i>Cell Communication and Signaling</i> , 2020, 18, 90.	2.7	56
192	Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis. <i>Lung Cancer</i> , 2020, 146, 42-49.	0.9	25
193	Rational Cancer Treatment Combinations: An Urgent Clinical Need. <i>Molecular Cell</i> , 2020, 78, 1002-1018.	4.5	95
194	Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1274-1288.	2.3	27
195	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1409-1424.	0.5	182
196	ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer. <i>Oncotarget</i> , 2020, 9, 1758003.	2.1	13
197	Immunotherapy in non-small-cell lung cancer: from targeted molecules to resistance patterns. <i>Pharmacogenomics</i> , 2020, 21, 705-720.	0.6	9
198	Balancing the Count: Harmonizing Panel-Based Tumor Mutational Burden Assessment. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1106-1109.	0.5	1
199	Long-term survivors with immunotherapy in advanced NSCLC: is "cure"™ within reach?. <i>Translational Cancer Research</i> , 2020, 9, 409-414.	0.4	3
200	Advances in the Treatment of Non-Small Cell Lung Cancer. <i>Clinics in Chest Medicine</i> , 2020, 41, 237-247.	0.8	50
201	Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. <i>BMC Cancer</i> , 2020, 20, 557.	1.1	29
202	Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1778-1789.	1.1	34
203	Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. <i>Journal of Clinical Medicine</i> , 2020, 9, 1870.	1.0	16
204	Analysis of Immune Checkpoint Drug Targets and Tumor Proteotypes in Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2020, 10, 9805.	1.6	17

#	ARTICLE	IF	CITATIONS
205	Should immune checkpoint inhibitors be contraindicated in lung cancer patients with latent tuberculosis?. <i>Immunotherapy</i> , 2020, 12, 759-762.	1.0	1
206	Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: age, Eastern Cooperative Organization performance status 2, steroids and antibiotics. <i>Future Oncology</i> , 2020, 16, 1683-1690.	1.1	4
207	Association of Immune Checkpoint Inhibitor Therapy With Survival in Patients With Cancers With <i>MUC16</i> Variants. <i>JAMA Network Open</i> , 2020, 3, e205837.	2.8	18
208	Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints. <i>Clinical and Translational Medicine</i> , 2020, 10, 374-411.	1.7	33
209	Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. <i>Current Oncology Reports</i> , 2020, 22, 70.	1.8	11
210	ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2020, 31, 609-618.	0.6	100
211	Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept. <i>Frontiers in Medicine</i> , 2020, 7, 90.	1.2	31
212	KEYNOTE-407: changing the way we treat stage IV squamous non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 148-153.	1.3	5
213	First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. <i>European Journal of Cancer</i> , 2020, 130, 155-167.	1.3	98
214	Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2020, 80, 360-369.	0.6	5
215	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 914-947.	0.5	119
216	Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 142.	1.3	37
217	Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1177-1189.	0.5	81
218	E3 Ubiquitin Ligases as Immunotherapeutic Target in Atherosclerotic Cardiovascular Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 106.	1.1	5
219	Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis. <i>OncImmunology</i> , 2020, 9, 1748982.	2.1	23
220	The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis. <i>Translational Cancer Research</i> , 2020, 9, 3231-3241.	0.4	5
221	Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. <i>Cancer Treatment Reviews</i> , 2020, 89, 102067.	3.4	48
222	Pharmacogenomics for immunotherapy and immune-related cardiotoxicity. <i>Human Molecular Genetics</i> , 2020, 29, R186-R196.	1.4	7

#	ARTICLE	IF	CITATIONS
224	PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2093.	1.0	13
225	Immunotherapy discontinuation – how, and when? Data from melanoma as a paradigm. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 707-715.	12.5	57
226	Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy. <i>Cancers</i> , 2020, 12, 1609.	1.7	27
227	Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4427.	1.8	67
228	Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations. <i>Current Treatment Options in Oncology</i> , 2020, 21, 60.	1.3	6
229	Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 4842-4851.	3.2	72
230	Anti-PDL1 effect in squamous non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 406-409.	1.3	2
231	Immunotherapy combinations for the treatment of patients with solid tumors. <i>Future Oncology</i> , 2020, 16, 1715-1736.	1.1	6
232	The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis. <i>World Journal of Surgical Oncology</i> , 2020, 18, 150.	0.8	30
233	Is there hope in improving 5-year overall survival? – review of 5-year overall survival data from KEYNOTE-001. <i>Annals of Translational Medicine</i> , 2020, 8, 728-728.	0.7	0
234	A Review of ULK1-Mediated Autophagy in Drug Resistance of Cancer. <i>Cancers</i> , 2020, 12, 352.	1.7	47
235	Immunotherapy in lung cancer: the chemotherapy conundrum. <i>Chinese Clinical Oncology</i> , 2020, 9, 59-59.	0.4	15
236	The emerging development of tumor mutational burden in patients with NSCLC. <i>Future Oncology</i> , 2020, 16, 469-481.	1.1	2
237	Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: The potential of the abscopal effect. <i>Lung Cancer</i> , 2020, 142, 106-113.	0.9	28
238	Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 874-875.	13.9	6
240	Recent advances in targeted small-molecule inhibitor therapy for non-small-cell lung cancer – An update. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 580-584.	0.7	10
241	A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. <i>Lung Cancer</i> , 2020, 143, 1-11.	0.9	19
242	Prognostic Biomarkers for Melanoma Immunotherapy. <i>Current Oncology Reports</i> , 2020, 22, 25.	1.8	13

#	ARTICLE	IF	CITATIONS
244	Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. <i>International Journal of Molecular Sciences</i> , 2020, 21, 556.	1.8	21
245	Genomic profiling in oncology clinical practice. <i>Clinical and Translational Oncology</i> , 2020, 22, 1430-1439.	1.2	4
246	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 52-66.	1.3	52
247	Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 1608-1632.	0.8	301
248	Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 335-344.	1.5	12
249	The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2020, 147, 1163-1179.	2.3	16
250	Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer. <i>Pharmacotherapy</i> , 2020, 40, 239-255.	1.2	14
251	Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells. <i>Cancers</i> , 2020, 12, 331.	1.7	27
252	The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors. <i>Biomolecules</i> , 2020, 10, 666.	1.8	29
253	An annual review of the remarkable advances in lung cancer clinical research in 2019. <i>Journal of Thoracic Disease</i> , 2020, 12, 1056-1069.	0.6	20
254	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 661.	3.4	446
255	The Mystic Role of Tumor Mutational Burden in Selecting Patients With Lung Cancer for First-Line Immunotherapy. <i>JAMA Oncology</i> , 2020, 6, 674.	3.4	7
256	ESMO 2019 personal non-small lung cancer highlights. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 150-153.	0.3	1
257	Cancer immunotherapy: Current applications and challenges. <i>Cancer Letters</i> , 2020, 480, 1-3.	3.2	19
258	Peri-tumor administration of controlled release anti-CTLA-4 synergizes with systemic anti-PD-1 to induce systemic antitumor immunity while sparing autoimmune toxicity. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1737-1749.	2.0	6
259	Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2153-2160.	1.2	8
260	Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2020, 22, 41.	1.8	20
261	Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report. <i>Clinical Lung Cancer</i> , 2020, 21, 384-388.	1.1	11

#	ARTICLE	IF	CITATIONS
262	Frontiers in combining immune checkpoint inhibitors for advanced urothelial cancer management. <i>Current Opinion in Urology</i> , 2020, 30, 457-466.	0.9	2
263	Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort. , 2020, 8, e000613.		15
264	Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e159-e170.	1.8	7
265	Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 29.	6.9	146
266	Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 258.	1.3	35
267	Therapeutic Landscape of Metastatic Non-Small-Cell Lung Cancer in Canada in 2020. <i>Current Oncology</i> , 2020, 27, 52-60.	0.9	13
268	Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma. <i>Journal of Cellular Physiology</i> , 2021, 236, 507-522.	2.0	28
269	Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1393-1403.	2.0	25
270	How does the gut microbiome influence immune checkpoint blockade therapy?. <i>Immunology and Cell Biology</i> , 2021, 99, 361-372.	1.0	11
271	Bempegaldesleukin (BEMPEG ; NKTR –214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma. <i>International Journal of Cancer</i> , 2021, 148, 1928-1937.	2.3	8
272	Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-1 blocking antibodies in patients with advanced non-small cell lung cancer: A preliminary study. <i>Thoracic Cancer</i> , 2021, 12, 145-152.	0.8	12
273	PD-1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?. <i>Journal of Gene Medicine</i> , 2021, 23, e3294.	1.4	14
274	Efficacy of immune checkpoint inhibitors in elderly patients aged ≥75 years. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1777-1780.	2.0	8
275	Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer. <i>Future Oncology</i> , 2021, 17, 763-773.	1.1	30
276	Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 619-631.	2.0	80
277	Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. , 2021, 219, 107694.		79
278	Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?. <i>International Journal of Cancer</i> , 2021, 149, 31-41.	2.3	23
279	Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis. <i>Journal of Hepatology</i> , 2021, 74, 700-715.	1.8	60

#	ARTICLE	IF	CITATIONS
280	Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 671-690.	1.2	30
281	Enhancing anti-tumour efficacy with immunotherapy combinations. <i>Lancet, The</i> , 2021, 397, 1010-1022.	6.3	196
282	Durvalumab, with or without tremelimumab, plus platinum+etoposide versus platinum+etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2021, 22, 51-65.	5.1	356
283	Checkpoint inhibitors in NSCLC for the elderly: current challenges and perspectives. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 315-323.	1.1	7
284	Predicting immunotherapy response through genomics. <i>Current Opinion in Genetics and Development</i> , 2021, 66, 1-9.	1.5	12
285	Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1747-1756.	1.2	11
286	Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC. <i>Cancer Medicine</i> , 2021, 10, 3-14.	1.3	28
287	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory 'FoRECATT' study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1583-1592.	2.0	12
288	The cutting-edge progress of immune-checkpoint blockade in lung cancer. <i>Cellular and Molecular Immunology</i> , 2021, 18, 279-293.	4.8	102
289	Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: An overview. <i>Pharmacological Research</i> , 2021, 164, 105309.	3.1	12
290	Radiotherapy and Immunotherapy Combinations for Lung Cancer. <i>Current Oncology Reports</i> , 2021, 23, 4.	1.8	11
291	2020 Innovation-Based Optimism for Lung Cancer Outcomes. <i>Oncologist</i> , 2021, 26, e454-e472.	1.9	17
292	Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2021, 32, 395-403.	0.6	53
293	Immunotherapy combinations in advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2021, 33, 73-79.	1.1	5
294	Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors. <i>International Journal of Cancer</i> , 2021, 149, 277-286.	2.3	7
295	Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy. <i>Annals of Oncology</i> , 2021, 32, 295-297.	0.6	14
296	Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases. <i>Clinical Lung Cancer</i> , 2021, 22, 110-119.	1.1	27
297	Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 653-664.	0.5	251

#	ARTICLE	IF	CITATIONS
298	Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer: is there a role?. <i>Current Opinion in Oncology</i> , 2021, 33, 64-72.	1.1	3
299	Immune response drives outcomes in prostate cancer: implications for immunotherapy. <i>Molecular Oncology</i> , 2021, 15, 1358-1375.	2.1	48
300	Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Molecular Oncology</i> , 2021, 15, 887-900.	2.1	24
301	Neoadjuvant immunotherapy in nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2021, 33, 59-63.	1.1	6
302	Nivolumab: an investigational agent for the treatment of biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 325-332.	1.9	7
303	Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials. <i>Cancer</i> , 2021, 127, 709-719.	2.0	16
304	Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1177-1188.	2.0	60
305	Sicca Syndromes. , 2021, , 109-142.		2
306	Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110185.	1.4	12
307	TIGIT and PD1 Co-blockade Restores exÂvivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 443-464.	2.3	43
308	New Approved First-line Combining Therapy of NSCLC in 2020. <i>E3S Web of Conferences</i> , 2021, 245, 03057.	0.2	0
309	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Patients with Non-small Cell Lung Cancer of Squamous Histology: Focus on Afatinib. <i>Touch Reviews in Oncology & Haematology</i> , 2021, 17, 36.	0.1	0
310	Impact of Advantage in Tumor Response on the Correlation Between Progression-Free Survival and Overall Survival: Meta-Analysis of Clinical Trials in Patients with Advanced Non-Small Cell Lung Cancer. <i>Pharmaceutical Medicine</i> , 2021, 35, 81-92.	1.0	1
311	Checkpoint inhibition in the fight against cancer: NK cells have some to say in it. , 2021, , 267-304.		1
312	Digital Image Analysis for Estimating Stromal CD8+ Tumor-Infiltrating Lymphocytes in Lung Adenocarcinoma. <i>Journal of Pathology Informatics</i> , 2021, 12, 28.	0.8	7
313	Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 31-44.	1.4	23
314	Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab012.	1.4	16
315	Tofacitinib overcomes an IFNÎ³ â€induced decrease in NK cellâ€mediated cytotoxicity via the regulation of immuneâ€related molecules in LC â€ad. <i>Thoracic Cancer</i> , 2021, 12, 775-782.	0.8	5

#	ARTICLE	IF	CITATIONS
316	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th,) Tj ETQq0 0 0,rgBT /Over	1.8	0
317	Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. Translational Lung Cancer Research, 2021, 10, 202-220.	1.3	29
318	Nephrotoxicity of Immune Checkpoint Inhibitors: A Disproportionality Analysis from 2013 to 2020. Tohoku Journal of Experimental Medicine, 2021, 254, 275-282.	0.5	3
319	Immunotherapy-associated complete heart block in a patient with NSCLC: A case report and literature review. Respiratory Medicine Case Reports, 2021, 33, 101390.	0.2	3
320	Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells. Cancer Discovery, 2021, 11, 1100-1117.	7.7	85
321	Aberrant splicing isoforms detected by full-length transcriptome sequencing as transcripts of potential neoantigens in non-small cell lung cancer. Genome Biology, 2021, 22, 9.	3.8	58
322	The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review. Cancer Control, 2021, 28, 107327482199743.	0.7	30
323	The Impact of Priming Effect of Immune Checkpoint Inhibitor Therapy for Advanced Stage Non-Small Cell Lung Cancer: A Meta-Epidemiological Study. SSRN Electronic Journal, 0, , .	0.4	0
324	Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 590-606.	1.3	25
325	Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents. Cancer Immunology, Immunotherapy, 2021, 70, 1691-1704.	2.0	6
326	Baicalin Induces Apoptosis and Suppresses the Cell Cycle Progression of Lung Cancer Cells Through Downregulating Akt/mTOR Signaling Pathway. Frontiers in Molecular Biosciences, 2020, 7, 602282.	1.6	28
327	First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet, The, 2021, 397, 375-386.	6.3	638
328	Peripheral CD4+ T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer. Science China Life Sciences, 2021, 64, 1590-1601.	2.3	9
329	Systematic Review of Neoadjuvant Immunotherapy for Patients With Non-Small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery, 2021, 33, 850-857.	0.4	10
330	PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma. OncolImmunology, 2021, 10, 1960729.	2.1	8
331	Immune checkpoint inhibitors in mesothelioma: a turning point. Lancet, The, 2021, 397, 348-349.	6.3	15
332	Management of Brain Metastases. Current Cancer Research, 2021, , 115-137.	0.2	0
333	A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors. Clinical Cancer Research, 2021, 27, 2571-2583.	3.2	22

#	ARTICLE	IF	CITATIONS
334	KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 737-752.	1.3	28
335	Targeting glyco-immune checkpoints for cancer therapy. Expert Opinion on Biological Therapy, 2021, 21, 1063-1071.	1.4	12
336	The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 619010.	1.3	16
337	Immunotherapy in non-small cell lung cancer: advancements and challenges. Chinese Medical Journal, 2021, 134, 1135-1137.	0.9	4
338	Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non-small cell lung cancer. Thoracic Cancer, 2021, 12, 949-957.	0.8	8
339	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 198-211.	5.1	773
340	An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT). J Clin Oncol, 2021, 39, 1077-1085.	1.7	10
341	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nature Medicine, 2021, 27, 504-514.	15.2	357
342	Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. Blood, 2021, 137, e001818.		14
343	Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis. Thoracic Cancer, 2021, 12, 1058-1066.	0.8	18
344	Biology of NSCLC: Interplay between Cancer Cells, Radiation and Tumor Immune Microenvironment. Cancers, 2021, 13, 775.	1.7	9
345	Optimal Therapy for Advanced Non-Small Cell Lung Cancer Without Driver Alterations. JNCI Cancer Spectrum, 2021, 5, pkab014.	1.4	0
346	The evolving landscape of immunotherapy in solid tumors. Journal of Surgical Oncology, 2021, 123, 798-806.	0.8	17
347	FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non-small Cell Lung Cancer, A Collaborative Project Orbis Review. Clinical Cancer Research, 2021, 27, 3522-3527.	3.2	32
348	Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Medicine, 2021, 8, 627089.	1.2	9
349	Evolving landscape and academic attitudes toward the controversies of global immunoncology trials. International Journal of Cancer, 2021, 149, 108-118.	2.3	5
350	Immune checkpoint inhibitors: Significant advancements in non-small cell lung cancer treatment. American Journal of Health-System Pharmacy, 2021, 78, 769-780.	0.5	11
351	Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. Lung Cancer, 2021, 152, 109-118.	0.9	14

#	ARTICLE	IF	CITATIONS
352	Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?. ImmunoTargets and Therapy, 2021, Volume 10, 9-26.	2.7	14
353	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology, 2021, 18, 345-362.	12.5	646
354	G-quadruplexes: a promising target for cancer therapy. Molecular Cancer, 2021, 20, 40.	7.9	239
355	Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity. Journal of Experimental and Clinical Cancer Research, 2021, 40, 74.	3.5	19
356	CheckMate 9LA: broadening treatment options for patients with non-small-cell lung cancer. Lancet Oncology, The, 2021, 22, 157-159.	5.1	10
357	Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Cancers, 2021, 13, 987.	1.7	38
358	Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. Current Oncology, 2021, 28, 1094-1113.	0.9	12
359	Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients. ESMO Open, 2021, 6, 100013.	2.0	2
360	Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. , 2021, 9, e001945.		74
361	Recent developments in cancer research: Expectations for a new remedy. Annals of Gastroenterological Surgery, 2021, 5, 419-426.	1.2	12
362	The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis. Cancer Management and Research, 2021, Volume 13, 1383-1393.	0.9	5
364	Management of brain metastases from lung cancer in the era of immunotherapy: a review of the literature. Future Oncology, 2021, 17, 597-609.	1.1	3
365	Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators. , 2021, 9, e001819.		19
366	Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?. Frontiers in Pharmacology, 2021, 12, 572845.	1.6	6
367	Immune checkpoint inhibitors. Journal of Experimental Medicine, 2021, 218, .	4.2	27
368	Efficacy and safety of carboplatin and pemetrexed followed by maintenance with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer: A single-arm, open-label, multicenter, phase II study. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 486-494.	0.7	1
369	Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes. Frontiers in Immunology, 2020, 11, 629722.	2.2	75
370	Immunotherapy in lung cancer. Journal of Surgical Oncology, 2021, 123, 718-729.	0.8	7

#	ARTICLE	IF	CITATIONS
371	Concerns and controversies regarding ipilimumab-based immunotherapy in the first-line treatment of non-small cell lung cancer. <i>Precision Cancer Medicine</i> , 0, 4, 7-7.	1.8	0
372	The Entire Intestinal Tract Surveillance Using Capsule Endoscopy after Immune Checkpoint Inhibitor Administration: A Prospective Observational Study. <i>Diagnostics</i> , 2021, 11, 543.	1.3	3
373	PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3975-3989.	3.3	25
374	Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. <i>Cancers</i> , 2021, 13, 1300.	1.7	10
375	Peripheral Blood Autoantibodies Against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint Inhibitor-Based Treatment in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 625578.	1.3	8
376	Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1128-1155.	1.1	4
377	A novel panel based on immune infiltration and tumor mutational burden for prognostic prediction in hepatocellular carcinoma. <i>Aging</i> , 2021, 13, 8563-8587.	1.4	8
378	Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?. <i>Pharmaceuticals</i> , 2021, 14, 288.	1.7	21
379	Agonistic CD40 Antibodies in Cancer Treatment. <i>Cancers</i> , 2021, 13, 1302.	1.7	50
380	The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma. <i>Molecules</i> , 2021, 26, 1392.	1.7	21
381	<i>LRP1B</i> mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. , 2021, 9, e001792.		63
382	Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art. <i>Cancer Communications</i> , 2021, 41, 287-302.	3.7	74
383	Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Clinical Lung Cancer</i> , 2021, 22, 500-509.	1.1	13
384	Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/L1 directed immune checkpoint inhibition.. <i>Journal of Immunological Methods</i> , 2021, 490, 112956.	0.6	5
385	Association between ¹⁸ F-FDG metabolic activity and programmed death ligand-1 (PD-L1) expression using 22C3 immunohistochemistry assays in non-small cell lung cancer (NSCLC) resection specimens. <i>British Journal of Radiology</i> , 2021, 94, 20200397.	1.0	8
386	A recombinant influenza virus with a CTLA4-specific scFv inhibits tumor growth in a mouse model. <i>Cell Biology International</i> , 2021, 45, 1202-1210.	1.4	12
387	Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 705-713.	1.1	4
388	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 723-733.	0.8	329

#	ARTICLE	IF	CITATIONS
389	Autoantibody Positivity Is a Risk Factor for Chemotherapy-induced Exacerbation of Interstitial Pneumonia in Lung Cancer. <i>Anticancer Research</i> , 2021, 41, 1497-1506.	0.5	2
391	If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3025.	1.8	5
392	Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy. <i>Cancers</i> , 2021, 13, 1562.	1.7	10
393	Integrative Characterization of Immune-relevant Genes in Hepatocellular Carcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	5
394	Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC). <i>Current Treatment Options in Gastroenterology</i> , 2021, 19, 351-368.	0.3	6
395	Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 611012.	1.3	16
396	Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study. <i>Cancers</i> , 2021, 13, 1413.	1.7	13
397	Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1057-1064.	1.0	2
398	Nivolumab Immunotherapy Plus Hydrogen Inhalation for Treatment of KRAS-Mutant Pulmonary Sarcomatoid Carcinoma: A Case Report. <i>Nano LIFE</i> , 2021, 11, 2140003.	0.6	1
399	Efficacy of Anti-PD-1/PD-L1 Monotherapy or Combinational Therapy in Patients Aged 75 Years or Older: A Study-Level Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 538174.	1.3	11
400	NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 254-266.	2.3	628
401	Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3369-3379.	1.2	21
402	The Association Between Inflammation and Immunosuppression: Implications for ICI Biomarker Development. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2053-2064.	1.0	12
403	Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review. <i>Frontiers in Immunology</i> , 2021, 12, 627197.	2.2	12
404	Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 589-598.	1.4	17
405	T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. <i>Nature Communications</i> , 2021, 12, 1402.	5.8	85
406	Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. <i>AAPS Journal</i> , 2021, 23, 39.	2.2	356
407	PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 301.	1.1	42

#	ARTICLE	IF	CITATIONS
409	Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs). Lung Cancer: Targets and Therapy, 2021, Volume 12, 21-34.	1.3	10
410	KRAS G12C inhibition and innate immune targeting. Expert Opinion on Therapeutic Targets, 2021, 25, 1-8.	1.5	6
411	Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma. International Journal of Molecular Sciences, 2021, 22, 3302.	1.8	9
412	Safety of current immune checkpoint inhibitors in non-small cell lung cancer. Expert Opinion on Drug Safety, 2021, 20, 651-667.	1.0	4
413	A five-m6A regulatory gene signature is a prognostic biomarker in lung adenocarcinoma patients. Aging, 2021, 13, 10034-10057.	1.4	12
414	First-line Immunotherapy for Advanced Non-small-cell Lung Cancer. Japanese Journal of Lung Cancer, 2021, 61, 88-94.	0.0	0
415	Repurposing Anticancer Drugs for the Treatment of Idiopathic Pulmonary Fibrosis and Antifibrotic Drugs for the Treatment of Cancer: State of the Art. Current Medicinal Chemistry, 2021, 28, 2234-2247.	1.2	7
416	First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1. Journal of Thoracic Oncology, 2021, 16, 665-676.	0.5	30
417	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. Immunotherapy, 2021, 13, 419-432.	1.0	9
418	Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges. Cancer Letters, 2021, 502, 166-179.	3.2	16
419	Malignant Pleural Effusions—A Window Into Local Anti-Tumor T Cell Immunity?. Frontiers in Oncology, 2021, 11, 672747.	1.3	9
420	Radiation for Oligometastatic Lung Cancer in the Era of Immunotherapy: What Do We (Need to) Know?. Cancers, 2021, 13, 2132.	1.7	5
421	Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer. BioMed Research International, 2021, 2021, 1-8.	0.9	4
422	From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era—chemo-free or chemo-reform?. Translational Lung Cancer Research, 2021, 10, 1924-1927.	1.3	7
423	Development of Immunotherapy Combination Strategies in Cancer. Cancer Discovery, 2021, 11, 1368-1397.	7.7	130
424	Predictive biomarkers for response to immune checkpoint inhibition. Seminars in Cancer Biology, 2022, 79, 4-17.	4.3	70
425	Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines. Trends in Immunology, 2021, 42, 293-311.	2.9	62
426	Routine Molecular Pathology Diagnostics in Precision Oncology. Deutsches Ärzteblatt International, 2021, 118, .	0.6	2

#	ARTICLE	IF	CITATIONS
427	MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 625593.	1.6	7
428	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 686-696.	0.5	13
429	The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 \geq 50% advanced non-small-cell lung cancer. <i>ESMO Open</i> , 2021, 6, 100078.	2.0	35
430	PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression \geq 50%: Selecting the best strategy. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103302.	2.0	18
431	Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations. <i>Immunotherapy</i> , 2021, 13, 509-525.	1.0	3
433	Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study. <i>BMC Cancer</i> , 2021, 21, 346.	1.1	21
434	Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1165-1184.	0.8	54
435	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2021, 2021, CD013257.	1.5	35
436	Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue. <i>Scientific Reports</i> , 2021, 11, 8511.	1.6	24
437	The Next Decade of Immune Checkpoint Therapy. <i>Cancer Discovery</i> , 2021, 11, 838-857.	7.7	363
438	Endocrine toxicities of immune checkpoint inhibitors. <i>Nature Reviews Endocrinology</i> , 2021, 17, 389-399.	4.3	162
439	Liver Metastasis Irradiation Can Restore Immunotherapeutic Responsiveness. <i>Trends in Immunology</i> , 2021, 42, 275-277.	2.9	0
440	A Pilot Study of Short-course Nivolumab and Low-dose Ipilimumab for Adjuvant Treatment of Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 254-257.	0.6	2
441	Prognostic and Predictive Biomarkers in Non-Small Cell Lung Cancer Patients on Immunotherapyâ€”The Role of Liquid Biopsy in Unraveling the Puzzle. <i>Cancers</i> , 2021, 13, 1675.	1.7	20
442	A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers. <i>BMC Cancer</i> , 2021, 21, 441.	1.1	25
443	Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC. <i>Cancers</i> , 2021, 13, 1949.	1.7	31
444	What a general practitioner should know about bronchogenic carcinoma. <i>Medicina Pro Praxi</i> , 2021, 18, 63-67.	0.0	0
445	Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer. <i>Cancers</i> , 2021, 13, 1682.	1.7	16

#	ARTICLE	IF	CITATIONS
446	Resistance mechanisms to checkpoint inhibitors. <i>Current Opinion in Immunology</i> , 2021, 69, 47-55.	2.4	19
447	Strategies to overcome resistance to immune checkpoint blockade in lung cancer. <i>Lung Cancer</i> , 2021, 154, 151-160.	0.9	25
449	Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol. <i>The Cochrane Library</i> , 0, , .	1.5	0
450	Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 621639.	1.3	12
451	Identification of inhibitory immune checkpoints and relevant regulatory pathways in breast cancer stem cells. <i>Cancer Medicine</i> , 2021, 10, 3794-3807.	1.3	8
452	Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. , 2021, 9, e002121.		30
453	A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. , 2021, 9, e002032.		6
454	Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 611-620.	1.9	4
455	Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-â€“Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2021, 4, e218787.	2.8	26
456	KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup. <i>Frontiers in Oncology</i> , 2021, 11, 672612.	1.3	38
457	Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2972-2980.	1.4	5
458	Association Between FSIP2 Mutation and an Improved Efficacy of Immune Checkpoint Inhibitors in Patients With Skin Cutaneous Melanoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 629330.	1.6	3
459	Beyond PACIFIC: Uncharted Waters. <i>Journal of Thoracic Oncology</i> , 2021, 16, 715-718.	0.5	0
460	Nanotechnology: Breaking the Current Treatment Limits of Lung Cancer. <i>Advanced Healthcare Materials</i> , 2021, 10, e2100078.	3.9	40
461	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 2653.	1.7	2
462	Recognition and Management of Toxicities from Immunotherapy and Targeted Therapy in Elderly Patients with Lung Cancer. <i>Advances in Oncology</i> , 2021, 1, 73-84.	0.1	0
463	Expanding the Role of Checkpoint Inhibitors in Immune Cold Tumors. <i>Advances in Oncology</i> , 2021, 1, 85-95.	0.1	0
464	Immunotherapy for Glioblastoma: Current Progress and Challenges. <i>Frontiers in Immunology</i> , 2021, 12, 676301.	2.2	83

#	ARTICLE	IF	CITATIONS
465	Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB ² harmonization project comparing three NGS panels. , 2021, 9, e001904.		16
466	Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 662392.	1.3	3
468	Advances in systemic therapy for the first-line treatment of unresectable HCC. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 621-628.	1.1	11
469	Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021, 148, 76-91.	1.3	33
470	Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1623-1634.	1.4	10
471	Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity. <i>Cancer Discovery</i> , 2021, 11, 1008-1010.	7.7	15
472	An update on companion and complementary diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 445-454.	1.5	4
473	Precision Oncology. <i>Advances in Oncology</i> , 2021, 1, 97-112.	0.1	0
474	The imaging of immunotherapy-related hypophysitis and other pituitary lesions in oncology patients. <i>Clinical Radiology</i> , 2021, 76, 325-332.	0.5	14
475	Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity. <i>British Journal of Dermatology</i> , 2021, 185, 627-635.	1.4	12
476	Targeting Solid Tumors Using CD3 Bispecific Antibodies. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1350-1358.	1.9	8
477	Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung. <i>BMC Cancer</i> , 2021, 21, 731.	1.1	4
478	Post-immunotherapy imaging in lung cancer. <i>Clinical Radiology</i> , 2022, 77, 44-57.	0.5	3
479	Lung Cancer Stem Cellsâ€™ Origin, Diagnostic Techniques and Perspective for Therapies. <i>Cancers</i> , 2021, 13, 2996.	1.7	14
480	Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management. <i>Frontiers in Endocrinology</i> , 2021, 12, 649863.	1.5	24
481	Hospitalizations in solid tumor phase I clinical trial patients: Incidence, pattern and clinical outcomes at an Australian phase I clinical trial unit. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, , .	0.7	0
482	Correlation analysis of tumor mutation burden of hepatocellular carcinoma based on data mining. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1117-1131.	0.6	7
483	Simple parameters to solve a complex issue: predicting response to checkpoint inhibitor therapy in lung cancer. <i>Lung Cancer Management</i> , 2021, 10, LMT44.	1.5	3

#	ARTICLE	IF	CITATIONS
484	Vitamin D Supplementation Regulates Postoperative Serum Levels of PD-L1 in Patients with Digestive Tract Cancer and Improves Survivals in the Highest Quintile of PD-L1: A Post Hoc Analysis of the AMATERASU Randomized Controlled Trial. <i>Nutrients</i> , 2021, 13, 1987.	1.7	16
485	Two Complementarity Immunotherapeutics in Non-Small-Cell Lung Cancer Patientsâ€™ Mechanism of Action and Future Concepts. <i>Cancers</i> , 2021, 13, 2836.	1.7	3
486	Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 2800.	1.7	2
487	Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma. <i>Drugs</i> , 2021, 81, 971-984.	4.9	5
488	Turning â€˜Coldâ€™ tumors â€˜Hotâ€™: immunotherapies in sarcoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1039-1039.	0.7	21
489	Advances in Immunotherapy and Implications for Current Practice in Nonâ€™Small-Cell Lung Cancer. <i>JCO Oncology Practice</i> , 2021, 17, 662-668.	1.4	14
490	Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database. <i>Clinical Drug Investigation</i> , 2021, 41, 615-627.	1.1	3
491	E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in nonâ€™small cell lung cancer. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	18
492	Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States. <i>Pharmaceutics</i> , 2021, 13, 912.	2.0	2
493	Higher Tumor Mutation Burden Was a Predictor for Better Outcome for NSCLC Patients Treated with PD-1 Antibodies: A Systematic Review and Meta-analysis. <i>SLAS Technology</i> , 2021, 26, 605-614.	1.0	8
494	Immunotherapy for Advanced Nonâ€™Small Cell Lung Cancer: A Decade of Progress. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e105-e127.	1.8	67
495	The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV nonâ€™small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 1519-1530.	0.7	3
496	Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients. <i>Journal of Molecular Pathology</i> , 2021, 2, 197-206.	0.5	2
497	The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2752-2765.	1.3	5
498	Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2937-2954.	1.3	19
499	The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials. <i>ESMO Open</i> , 2021, 6, 100124.	2.0	75
500	Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial. , 2021, 9, e002296.		45
501	Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. <i>Cancers</i> , 2021, 13, 3164.	1.7	35

#	ARTICLE	IF	CITATIONS
502	Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 205.	1.5	15
503	Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer. <i>Chinese Medical Journal</i> , 2021, 134, 1780-1788.	0.9	7
504	Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. <i>Molecular Cell</i> , 2021, 81, 2317-2331.e6.	4.5	97
505	Aging- and Tumor-Mediated Increase in CD8+CD28 ^{hi} T Cells Might Impose a Strong Barrier to Success of Immunotherapy in Glioblastoma. <i>ImmunoHorizons</i> , 2021, 5, 395-409.	0.8	8
506	<i>CDKN2A</i> Alterations and Response to Immunotherapy in Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4025-4035.	3.2	51
507	A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2766-2778.	1.3	9
508	ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 219-228.	2.0	5
509	Immune cell - produced ROS and their impact on tumor growth and metastasis. <i>Redox Biology</i> , 2021, 42, 101891.	3.9	72
510	Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 625-644.	12.5	148
511	Personalized Medicine in Oncology in the Developing World: Barriers and Concepts to Improve <i>Current Status Quo</i> . <i>World Journal of Oncology</i> , 2021, 12, 50-60.	0.6	14
512	TMB in NSCLC: A Broken Dream?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6536.	1.8	31
513	Pan-cancer analysis of <i>CD274</i> (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression. , 2021, 9, e002558.		7
514	Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). <i>Vaccines</i> , 2021, 9, 689.	2.1	9
515	The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 702924.	1.3	6
516	Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3014-3028.	1.3	9
517	Integrated functional and spatial profiling of tumour immune responses induced by immunotherapy: the iPROFILER platform. <i>Immuno-Oncology Technology</i> , 2021, 10, 100034.	0.2	2
518	Immune checkpoints and liver resection after neoadjuvant chemotherapy including bevacizumab in patients with microsatellite-stable colorectal liver metastases. <i>Hpb</i> , 2022, 24, 40-46.	0.1	0
519	Efficacy of PD-1 or PD-L1 Inhibitors and Central Nervous System Metastases in Advanced Cancer: A Meta-Analysis. <i>Current Cancer Drug Targets</i> , 2021, 21, .	0.8	1

#	ARTICLE	IF	CITATIONS
520	A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4566-4573.	3.2	13
521	A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 240.	3.5	3
522	Immunoterapia en oncología de las vías aerodigestivas superiores. <i>EMC - Otorrinolaringología</i> , 2021, 50, 1-20.	0.0	0
523	Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1872-1882.	0.5	85
524	Rapid Serial Immunoprofiling of the Tumor Immune Microenvironment by Fine Needle Sampling. <i>Clinical Cancer Research</i> , 2021, 27, 4781-4793.	3.2	14
525	Role of PD-L1 assessment in advanced NSCLC. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, 1084-1085.	0.7	1
526	CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, e264-e268.	1.1	17
527	Brain Metastases Status and Immunotherapy Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 669398.	2.2	10
528	Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. <i>Annals of Oncology</i> , 2021, 32, 881-895.	0.6	213
529	Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \geq 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2327-2338.	0.8	146
530	Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives. <i>Pharmacological Research</i> , 2021, 169, 105643.	3.1	13
531	Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 495-508.	21.5	120
532	Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 573852.	1.6	11
533	Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments. <i>Clinical Lung Cancer</i> , 2021, 22, 483-499.	1.1	11
534	Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA. <i>Clinical Lung Cancer</i> , 2021, 22, 292-300.e1.	1.1	4
535	Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 959-969.	5.1	222
536	Cost-Minimization Analysis of Pembrolizumab Monotherapy Versus Nivolumab in Combination with Ipilimumab as First-Line Treatment for Metastatic PD-L1-Positive Non-small Cell Lung Cancer: A US Payer Perspective. <i>Pharmacoeconomics - Open</i> , 2021, 5, 765-778.	0.9	1
537	Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis. , 2021, 9, e002732.		12

#	ARTICLE	IF	CITATIONS
538	Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1099-1117.	0.5	64
539	The biology of combination immunotherapy in recurrent metastatic head and neck cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 136, 106002.	1.2	6
540	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		41
541	A Rare Presentation of Checkpoint Inhibitor Induced Distal RTA. <i>Case Reports in Oncological Medicine</i> , 2021, 2021, 1-5.	0.2	2
542	Immunotherapy in Older Adults With Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2115-2127.	0.8	33
543	Neoantigen Controversies. <i>Annual Review of Biomedical Data Science</i> , 2021, 4, 227-253.	2.8	9
544	Hypersensitivity and Immune-related Adverse Events in Biologic Therapy. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 62, 413-431.	2.9	6
545	Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1883-1892.	0.5	93
546	Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Pharmacology</i> , 2021, 12, 678409.	1.6	15
547	CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study. , 2021, 9, e002446.		16
548	Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential. <i>Frontiers in Immunology</i> , 2021, 12, 697083.	2.2	33
549	The safety of current treatment options for advanced esophageal cancer after first-line chemotherapy. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 55-65.	1.0	11
550	Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?â€”a trial-level meta-analysis in PD-L1 selected subgroups. <i>Translational Lung Cancer Research</i> , 2021, 10, 3106-3119.	1.3	28
551	Classification of Lung Adenocarcinoma Based on Immune Checkpoint and Screening of Related Genes. <i>Journal of Oncology</i> , 2021, 2021, 1-12.	0.6	6
552	Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%. <i>Advances in Therapy</i> , 2021, 38, 4354-4365.	1.3	7
553	Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1086-1098.	0.5	53
554	Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. <i>Frontiers in Pharmacology</i> , 2021, 12, 714483.	1.6	9
555	The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: A meta-analysis. <i>International Immunopharmacology</i> , 2021, 96, 107594.	1.7	11

#	ARTICLE	IF	CITATIONS
556	Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 3828.	1.7	6
557	Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data. <i>Lung Cancer Management</i> , 2021, 10, LMT51.	1.5	10
558	First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti-PD-L1 Probody. <i>Clinical Cancer Research</i> , 2021, 27, 5325-5333.	3.2	19
559	Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b Trial. <i>Clinical Lung Cancer</i> , 2022, 23, 273-281.	1.1	6
560	The Clinical Application of Neoantigens in Esophageal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 703517.	1.3	8
561	Characterizing the Metabolic and Immune Landscape of Non-small Cell Lung Cancer Reveals Prognostic Biomarkers Through Omics Data Integration. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 702112.	1.8	7
562	Current cancer therapies and their influence on glucose control. <i>World Journal of Diabetes</i> , 2021, 12, 1010-1025.	1.3	10
563	A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression. <i>Frontiers in Oncology</i> , 2021, 11, 676732.	1.3	14
564	Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2 ⁺ negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 1-13.	1.1	3
565	A clinical variable-based nomogram could predict the survival for advanced NSCLC patients receiving second-line atezolizumab. <i>Cancer Medicine</i> , 2021, 10, 6218-6226.	1.3	2
566	Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer. <i>Cell Death and Disease</i> , 2021, 12, 741.	2.7	15
567	Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score $\geq 50\%$. <i>Journal of Clinical Oncology</i> , 2021, 39, 2339-2349.	0.8	468
568	Paradigm shift in the management of metastatic nonsmall cell lung cancer. <i>International Journal of Clinical Practice</i> , 2021, 75, e14533.	0.8	0
569	TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 699895.	2.2	102
570	Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Cancer Research and Treatment</i> , 2022, 54, 424-433.	1.3	11
571	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. <i>EClinicalMedicine</i> , 2021, 37, 100940.	3.2	11
572	Association Between Efficacy of Immune Checkpoint Inhibitors and Sex: An Updated Meta-Analysis on 21 Trials and 12,675 Non-Small Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 627016.	1.3	7
573	First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly. <i>Current Oncology Reports</i> , 2021, 23, 119.	1.8	4

#	ARTICLE	IF	CITATIONS
574	The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2021, 38, 100990.	3.2	34
575	Lung cancer. <i>Lancet, The</i> , 2021, 398, 535-554.	6.3	896
576	The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence. <i>Cancer Cell International</i> , 2021, 21, 454.	1.8	19
577	The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3,) Tj ETQq1 1 0.784314 rg 36	1.8	36
578	Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy. <i>Future Oncology</i> , 2021, 17, 2940-2949.	1.1	11
579	Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges. <i>Chinese Medical Journal</i> , 2021, 134, 1908-1919.	0.9	2
580	Toward personalized treatment approaches for non-small-cell lung cancer. <i>Nature Medicine</i> , 2021, 27, 1345-1356.	15.2	338
581	New approaches to managing relapsed/refractory Hodgkin lymphoma: the role of checkpoint inhibitors and beyond. <i>Expert Review of Hematology</i> , 2021, 14, 741-750.	1.0	0
582	PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain. <i>Diagnostics</i> , 2021, 11, 1452.	1.3	5
583	Multifunctional Nanocarriersâ€Mediated Synergistic Combination of Immune Checkpoint Inhibitor Cancer Immunotherapy and Interventional Oncology Therapy. <i>Advanced NanoBiomed Research</i> , 2021, 1, 2100010.	1.7	5
584	Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary. <i>Gynecologic Oncology</i> , 2021, 162, 421-430.	0.6	10
585	Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. <i>Scientific Reports</i> , 2021, 11, 17324.	1.6	24
586	Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 731546.	2.2	13
587	Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 4035.	1.7	18
589	Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 580459.	1.6	11
590	Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs. <i>Journal of Clinical Medicine</i> , 2021, 10, 3744.	1.0	11
591	Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100208.	0.6	0
592	Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis. <i>Cancer Cell International</i> , 2021, 21, 426.	1.8	7

#	ARTICLE	IF	CITATIONS
593	Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors. <i>JCO Oncology Practice</i> , 2022, 18, e175-e182.	1.4	12
594	The current knowledge concerning solid cancer and therapy. <i>Journal of Biochemical and Molecular Toxicology</i> , 2021, 35, e22900.	1.4	64
595	Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1410-1418.	15.2	168
596	Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition – Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry. <i>Frontiers in Oncology</i> , 2021, 11, 725549.	1.3	6
597	Comprehensive analysis of BTN3A1 in cancers: mining of omics data and validation in patient samples and cellular models. <i>FEBS Open Bio</i> , 2021, 11, 2586-2599.	1.0	16
598	BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 682007.	1.3	29
599	Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance. <i>Frontiers in Oncology</i> , 2021, 11, 739191.	1.3	6
600	Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)., 2021, 9, e002973.		26
601	Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer. <i>Chest</i> , 2021, 160, 731-742.	0.4	64
602	Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.1. <i>ESMO Open</i> , 2021, 6, 100198.	2.0	6
603	The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 987-996.	0.4	1
604	Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2637-2639.	0.8	4
605	Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application. <i>Immunotherapy</i> , 2021, 13, 1031-1051.	1.0	14
606	PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare. <i>Immunotherapy</i> , 2021, 13, 1053-1065.	1.0	16
607	Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 703143.	1.3	23
608	The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC. <i>Medicine (United States)</i> , 2021, 100, e27038.	0.4	9
609	The landscape of immune checkpoint inhibitor therapy in advanced lung cancer. <i>BMC Cancer</i> , 2021, 21, 968.	1.1	12
610	The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score ≥49%: a network meta-analysis. <i>Translational Lung Cancer Research</i> , 2021, 10, 3550-3566.	1.3	4

#	ARTICLE	IF	CITATIONS
611	Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. <i>European Journal of Internal Medicine</i> , 2021, 93, 87-94.	1.0	41
612	Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 704336.	1.3	29
613	Immunotherapy in Hepatocellular Carcinoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 87.	1.3	25
614	Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. <i>Cancer Discovery</i> , 2022, 12, 108-133.	7.7	165
615	Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2021, 32, 1597-1607.	0.6	47
616	Efficacy and safety of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitor versus chemotherapy for advanced lung cancer. <i>Medicine (United States)</i> , 2021, 100, e27121.	0.4	3
617	The Predictive Value of Clinical and Molecular Characteristics of Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Oncology</i> , 2021, 11, 732214.	1.3	11
618	Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2437-2446.	1.2	4
619	Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block. <i>Translational Lung Cancer Research</i> , 2021, 10, 3850-3854.	1.3	1
620	Atezolizumab: an investigational agent for the treatment of biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1007-1015.	1.9	2
621	KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer. <i>Investigational New Drugs</i> , 2022, 40, 43-57.	1.2	10
622	From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1: Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?. <i>Journal of Personalized Medicine</i> , 2021, 11, 914.	1.1	2
623	Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study. <i>Thrombosis Research</i> , 2021, 205, 29-39.	0.8	35
624	Human tissue cultures of lung cancer predict patient susceptibility to immune-checkpoint inhibition. <i>Cell Death Discovery</i> , 2021, 7, 264.	2.0	7
625	Therapeutic Rigid Bronchoscopy Intervention for Malignant Central Airway Obstruction Improves Performance Status to Allow Systemic Treatment. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2022, 29, 93-98.	0.8	2
626	Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. <i>Cancers</i> , 2021, 13, 4705.	1.7	86
627	Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2022, 12, a037895.	2.9	24
628	Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer. <i>Life</i> , 2021, 11, 1029.	1.1	8

#	ARTICLE	IF	CITATIONS
629	The promise of bispecific antibodies: Clinical applications and challenges. <i>Cancer Treatment Reviews</i> , 2021, 99, 102240.	3.4	28
630	NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images. <i>Cancers</i> , 2021, 13, 4543.	1.7	14
631	Metabolic Modifications, Inflammation, and Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 703681.	1.3	8
632	Dramatic Response to Pembrolizumab Monotherapy in a Patient With ARID1A-Mutant Lung Adenocarcinoma: Case Report. <i>Clinical Lung Cancer</i> , 2021, 22, e708-e711.	1.1	0
633	Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1. <i>Clinical Lung Cancer</i> , 2021, 22, 381-389.	1.1	4
634	ER expression associates with poor prognosis in male lung squamous carcinoma after radical resection. <i>BMC Cancer</i> , 2021, 21, 1043.	1.1	2
635	How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4719.	1.7	7
636	Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1368.	3.4	57
637	An Indirect Comparison Between Nivolumab + Ipilimumab + Two Cycles of Chemotherapy vs. Pembrolizumab + Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 698199.	1.3	5
638	A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. <i>Journal of Thoracic Oncology</i> , 2022, 17, 130-140.	0.5	49
640	Winds From the ORIENT: New Data to Inform RATIONAL Choice?. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1434-1436.	0.5	0
642	Patterns of Failure in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2021, 11, 724722.	1.3	3
643	Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1751-1756.	0.6	7
644	Combination strategies to maximize the benefits of cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2021, 14, 156.	6.9	202
645	Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small cell lung cancer treated with pembrolizumab. <i>Molecular Oncology</i> , 2021, 15, 2923-2940.	2.1	17
646	Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists. <i>British Journal of Cancer</i> , 2021, 125, 1210-1216.	2.9	10
647	The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy. <i>European Journal of Cancer</i> , 2021, 156, 93-108.	1.3	16
648	Hypoalbuminaemia as a Prognostic Biomarker of First-Line Treatment Resistance in Metastatic Non-small Cell Lung Cancer. <i>Frontiers in Nutrition</i> , 2021, 8, 734735.	1.6	16

#	ARTICLE	IF	CITATIONS
649	Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review. <i>Life</i> , 2021, 11, 1036.	1.1	7
650	Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy. <i>European Journal of Pharmacology</i> , 2021, 909, 174404.	1.7	18
651	Research Progress and Challenges in the Treatment of Central Nervous System Metastasis of Non-Small Cell Lung Cancer. <i>Cells</i> , 2021, 10, 2620.	1.8	10
652	Primary lung carcinoma in children and adolescents – Clinical characteristics and outcome of 12 cases from the German registry for rare paediatric tumours (STEP). <i>Lung Cancer</i> , 2021, 160, 66-72.	0.9	5
653	Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC. <i>Lung Cancer</i> , 2021, 161, 34-41.	0.9	7
654	In vivo two-photon characterization of tumor-associated macrophages and microglia (TAM/M) and CX3CR1 during different steps of brain metastasis formation from lung cancer. <i>Neoplasia</i> , 2021, 23, 1089-1100.	2.3	9
655	Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 100, 102280.	3.4	10
656	The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 161, 141-151.	0.9	5
657	Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study. <i>Lung Cancer</i> , 2021, 161, 180-188.	0.9	14
658	Combinatorial therapy in tumor microenvironment: Where do we stand?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188585.	3.3	48
659	The effects of anticancer therapies on bone metastases in breast cancer. , 2022, , 987-1002.		0
660	Delivery strategies to overcome tumor immunotherapy resistance. , 2022, , 529-547.		0
661	Development of Skin Rash Predicts Outcome of Anti-PD-1- and Anti-CTLA4-Based Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck: A Single-Center Analysis. <i>Oncology Research and Treatment</i> , 2021, 44, 538-546.	0.8	5
662	Tumor LAG^{β} and NY-ESO^{α} expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 619-630.	0.8	8
663	A pan-cancer study of PD-1 and CTLA-4 as therapeutic targets. <i>Translational Cancer Research</i> , 2021, 10, 3993-4001.	0.4	8
664	Immune Therapy: What Can We Learn From Acquired Resistance?. <i>Current Cancer Research</i> , 2021, , 75-114.	0.2	0
665	Tumor Microenvironment: Immune Effector and Suppressor Imbalance. <i>Current Cancer Research</i> , 2021, , 1-25.	0.2	0
666	A Method for the Establishment of Human Lung Adenocarcinoma Patient-Derived Xenografts in Mice. <i>Methods in Molecular Biology</i> , 2021, 2279, 165-173.	0.4	1

#	ARTICLE	IF	CITATIONS
667	The significance of Siglec-15 expression in resectable non-small cell lung cancer. <i>Neoplasma</i> , 2021, 67, 1204-1222.	0.7	12
668	Immunotherapy response modeling by ex-vivo organ culture for lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2223-2234.	2.0	9
671	Hematopoietic versus Solid Cancers and T Cell Dysfunction: Looking for Similarities and Distinctions. <i>Cancers</i> , 2021, 13, 284.	1.7	15
672	Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade. <i>JCI Insight</i> , 2021, 6, .	2.3	46
673	Comparison of an oncology clinical decision-support system's recommendations with actual treatment decisions. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021, 28, 832-838.	2.2	13
674	Neoadjuvant immunotherapy in early stage non-small cell lung cancer. <i>AME Medical Journal</i> , 0, 6, 42-42.	0.4	0
675	Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?. <i>Cancers</i> , 2021, 13, 360.	1.7	25
676	Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: A systematic review. <i>Journal of Cancer</i> , 2021, 12, 1318-1333.	1.2	27
677	Discovery of a novel anti PD-L1 X TIGIT bispecific antibody for the treatment of solid tumors.. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100467.	0.7	6
678	Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 25-31.	1.0	12
679	A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract. <i>Cancer Medicine</i> , 2021, 10, 1074-1083.	1.3	10
680	Tumor mutational burden on cytological samples: A pilot study. <i>Cancer Cytopathology</i> , 2021, 129, 460-467.	1.4	34
681	Hyperprogression: A novel response pattern under immunotherapy. <i>Clinical and Translational Medicine</i> , 2020, 10, e167.	1.7	22
683	Programmed Death Ligand 1 and Immune Cell Infiltrates in Solitary Fibrous Tumors of the Pleura. <i>Annals of Thoracic Surgery</i> , 2020, 112, 1862-1869.	0.7	1
684	Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer. <i>International Immunopharmacology</i> , 2020, 85, 106613.	1.7	24
685	Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. <i>New England Journal of Medicine</i> , 2020, 383, 1328-1339.	13.9	959
686	Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1047-1059.	1.4	9
687	Durvalumab for the treatment of PD-L1 non-small cell lung cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 95-105.	0.4	1

#	ARTICLE	IF	CITATIONS
688	Moving Immunotherapy Into Early-Stage Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 543-547.	1.0	5
690	Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma. , 2020, 8, e001675.		9
691	Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma. <i>Cancer Prevention Research</i> , 2021, 14, 313-324.	0.7	17
692	Emerging therapeutic agents for advanced non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 58.	6.9	161
693	Therapeutic options for advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer: a Bayesian network secondary analysis. <i>Aging</i> , 2020, 12, 7129-7162.	1.4	6
694	Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers. <i>Annals of Translational Medicine</i> , 2019, 7, 640-640.	0.7	103
695	CheckMate 227 trial has not checked the immune-strategy in first-line setting in advanced non-small cell lung cancer. <i>Translational Cancer Research</i> , 2020, 9, 2168-2170.	0.4	3
696	Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2020, 9, 2656-2673.	1.3	16
697	Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 9305-9321.	1.0	16
698	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. <i>Antibodies</i> , 2020, 9, 17.	1.2	14
699	Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks. <i>Journal of Clinical Medicine</i> , 2021, 10, 88.	1.0	19
700	Early palliative care of non-small cell lung cancer in the context of immunotherapy. <i>Oncology Letters</i> , 2020, 20, 396.	0.8	1
701	Mechanistic insight of predictive biomarkers for antitumor PD-1/PD-L1 blockade: A paradigm shift towards immunome evaluation (Review). <i>Oncology Reports</i> , 2020, 44, 424-437.	1.2	18
702	Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm. <i>Oncology Reviews</i> , 2020, 14, 490.	0.8	36
703	Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors. <i>Pharmaceutical Patent Analyst</i> , 2020, 9, 149-154.	0.4	4
704	Immunotherapy â€“ new perspective in lung cancer. <i>World Journal of Clinical Oncology</i> , 2020, 11, 250-259.	0.9	10
705	Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 899-906.	2.3	24
706	Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies. <i>Drugs in Context</i> , 2020, 9, 1-11.	1.0	34

#	ARTICLE	IF	CITATIONS
707	Epigenome signature as an immunophenotype indicator prompts durable clinical immunotherapy benefits in lung adenocarcinoma. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	10
708	Exacerbation of nontuberculous mycobacterial pulmonary disease in a patient with advanced non-small-cell lung cancer during treatment with PD-1 inhibitor and chemotherapy. <i>Respiratory Medicine Case Reports</i> , 2021, 34, 101529.	0.2	3
709	Algorithme thérapeutique des CBNPC sans anomalie moléculaire actionnable. <i>Revue Des Maladies Respiratoires Actualités</i> , 2021, 13, 2S121-2S134.	0.0	0
711	The efficacy of immune checkpoint inhibitors in thoracic malignancies. <i>European Respiratory Review</i> , 2021, 30, 200387.	3.0	5
712	Long-Term Favorable Outcome With Nivolumab in a Case of Advanced Non-Small Cell Lung Cancer: A Case Report. <i>Cureus</i> , 2021, 13, e18526.	0.2	0
713	First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 289-308.	0.5	173
714	Case Report: Pulmonary Metastases From Epithelioid Sarcoma in Extremity Favourably Responding to Immunotherapy With Camrelizumab. <i>Frontiers in Oncology</i> , 2021, 11, 728437.	1.3	2
715	A novel gene expression signature-based on B-cell proportion to predict prognosis of patients with lung adenocarcinoma. <i>BMC Cancer</i> , 2021, 21, 1098.	1.1	7
716	Real-World Incidence of Immune-Related Adverse Events Associated with Nivolumab Plus Ipilimumab in Patients with Advanced Renal Cell Carcinoma: A Retrospective Observational Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4767.	1.0	3
717	Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 686876.	1.6	9
718	Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab. , 2021, 9, e003395.		7
719	Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients with Liver Metastases: A Network Meta-Analysis of Nine Randomized Controlled Trials. <i>Cancer Research and Treatment</i> , 2022, 54, 803-816.	1.3	5
720	A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naïve Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study). <i>Clinical Lung Cancer</i> , 2022, 23, e285-e288.	1.1	12
721	PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4583.	1.0	3
722	Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis. <i>BMC Pulmonary Medicine</i> , 2021, 21, 309.	0.8	2
723	First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 expression: a systematic review and network meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1345-1355.	2.0	5
724	COVID and Lung Cancer. <i>Current Oncology Reports</i> , 2021, 23, 134.	1.8	21
725	First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. <i>ESMO Open</i> , 2021, 6, 100273.	2.0	91

#	ARTICLE	IF	CITATIONS
726	Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. <i>Annals of Oncology</i> , 2022, 33, 42-56.	0.6	56
727	Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?. <i>Cancers</i> , 2021, 13, 5065.	1.7	13
728	Comparative efficacy of treatments for brain metastases from non-small-cell lung cancer without an EGFR-mutation/ALK-rearrangement: a systematic review and network meta-analysis. <i>World Neurosurgery</i> , 2021, 158, e87-e87.	0.7	2
729	Association of the Geriatric Nutritional Risk Index With the Survival of Patients With Non-“Small Cell Lung Cancer After Nivolumab Therapy. <i>Journal of Immunotherapy</i> , 2022, 45, 125-131.	1.2	17
730	The role of immunotherapy in treating lung cancer: current status and future perspective. <i>Future Drug Discovery</i> , 0, , .	0.8	1
731	PRMT5: An Emerging Target for Pancreatic Adenocarcinoma. <i>Cancers</i> , 2021, 13, 5136.	1.7	11
732	Down-Regulated CLDN10 Predicts Favorable Prognosis and Correlates With Immune Infiltration in Gastric Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 747581.	1.1	7
733	Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5134.	1.7	8
734	Body composition and inflammation impact in non-small-cell lung cancer patients treated by first-line immunotherapy. <i>Immunotherapy</i> , 2021, 13, 1501-1519.	1.0	5
735	A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade. <i>Annual Review of Medicine</i> , 2022, 73, 231-250.	5.0	11
736	Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1247-1255.	2.0	9
737	Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. , 2021, 9, e002919.		30
738	Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 326.	3.5	19
739	CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. <i>Scientific Reports</i> , 2021, 11, 20059.	1.6	53
740	The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11061.	1.8	49
741	Immunotherapeutic Advances for NSCLC. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 399-417.	3.0	9
743	Tumour burden and efficacy of immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 75-90.	12.5	111
744	Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study. <i>EBioMedicine</i> , 2021, 73, 103630.	2.7	6

#	ARTICLE	IF	CITATIONS
745	Systemic Therapy in Nonsmall Cell Lung Cancer and the Role of Biomarkers in Selection of Treatment. <i>Thoracic Surgery Clinics</i> , 2021, 31, 399-406.	0.4	1
746	Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review. <i>European Journal of Cancer</i> , 2021, 158, 47-62.	1.3	32
747	Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188636.	3.3	27
748	A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors. <i>Cancer Treatment Reviews</i> , 2021, 101, 102300.	3.4	8
749	The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors. <i>Lung Cancer</i> , 2021, 162, 36-41.	0.9	5
750	A Case of Acute Heart Failure Following Immunotherapy for Metastatic Lung Cancer. <i>Cureus</i> , 2020, 12, e8093.	0.2	7
752	Immunotherapy in hepatocellular carcinoma: Combination strategies. <i>World Journal of Meta-analysis</i> , 2020, 8, 190-209.	0.1	1
753	Clinical efficacy, predictive biomarkers and response patterns of immunotherapy combinations for patients with cancer. <i>Future Oncology</i> , 2020, 16, 1659-1664.	1.1	2
755	Tratamiento adyuvante de melanoma cutáneo : indicaciones y alternativas.. <i>Revista Colombiana De Hematología Y Oncología</i> , 2020, 7, 56-63.	0.0	0
756	Biomarkers for Immune Checkpoint Inhibitors. , 2021, , 449-463.		0
757	Bayesian Design for Identifying Cohort-Specific Optimal Dose Combinations Based on Multiple Endpoints: Application to a Phase I Trial in Non-Small Cell Lung Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11452.	1.2	1
758	JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma. , 2021, 9, e003288.		9
759	Cut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF- κ B pathway in pancreatic cancer. <i>Cell Death and Disease</i> , 2021, 12, 1033.	2.7	22
760	First-line Cemiplimab versus Standard Chemotherapy in Advanced Non-small Cell Lung Cancer Patients with at Least 50% Programmed Cell Death Receptor Ligand-1 Positivity: Analysis of Cost-effectiveness. <i>Clinical Oncology</i> , 2022, 34, e123-e129.	0.6	4
761	Immunotherapy for Stage III NSCLC: Durvalumab and Beyond. <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 123-131.	1.3	4
762	CM227/CM9-LA: evidence supporting ipilimumab-based immunotherapy in the first-line treatment of metastatic NSCLC. <i>Precision Cancer Medicine</i> , 0, 3, 34-34.	1.8	0
764	A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player. <i>Translational Lung Cancer Research</i> , 2020, 9, 2479-2493.	1.3	10
765	The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma. <i>Internal Medicine</i> , 2022, 61, 1485-1490.	0.3	3

#	ARTICLE	IF	CITATIONS
766	Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy. European Oncology and Haematology, 2020, 16, 39.	0.0	0
767	Immunotherapy in Advanced Prostate Cancer. European Oncology and Haematology, 2020, 16, 44.	0.0	0
768	Targeting lung cancer using advanced drug delivery systems. , 2020, , 493-516.		4
769	A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies. Investigational New Drugs, 2020, 38, 1442-1447.	1.2	0
771	In search of goldilocks: the quest to optimize combination drug strategies for the management of advanced stage non-small-cell lung cancer. Translational Cancer Research, 2020, 9, 1311-1318.	0.4	0
772	Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors. JCO Precision Oncology, 2021, 5, 1625-1638.	1.5	10
773	Advances in systemic therapy for non-small cell lung cancer. BMJ, The, 2021, 375, n2363.	3.0	134
774	Immunotherapy in the First-Line Setting in Wild-Type NSCLC. Current Oncology, 2021, 28, 4457-4470.	0.9	10
775	Combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma: A meta-analysis of randomized controlled trials. Clinical Immunology, 2021, 232, 108876.	1.4	4
776	Sequencing Therapy for Patients With Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 945-948.	2.3	0
779	How I Treat Non–Small Cell Lung Cancer Refractory to Immunotherapy. Cancer Journal (Sudbury, Mass), 2020, 26, 507-516.	1.0	1
780	Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non–Small Cell Lung Cancer. Cancer Journal (Sudbury, Mass), 2020, 26, 507-516.	1.0	4
781	Introduction by the Guest Editors. Cancer Journal (Sudbury, Mass), 2020, 26, 471-472.	1.0	0
783	New Strategies in the Treatment of Advanced Squamous Non-Small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2020, 60, 379-384.	0.0	0
784	A Randomized Phase 3 Trial of Palliative Radiation Therapy Versus Concurrent Chemotherapy and Palliative Radiation Therapy in Patients With Good Performance Status, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer With Symptoms Due to Intrathoracic Disease Who Are Not Suitable for Radical Chemo-Radiation Therapy: Results of the Trans-Tasman Radiation Oncology Group 11.03 Trial. Practical Radiation Oncology, 2020, 11, 252-263.	1.1	3
785	Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy. Anesthesia and Analgesia, 2021, 132, 374-383.	1.1	8
786	Infiltration of CD8 FOXP3 T cells, CD8 T cells, and FOXP3 T cells in non-small cell lung cancer microenvironment. International Journal of Clinical and Experimental Pathology, 2020, 13, 880-888.	0.5	11
787	Novel genetic variants of and involved in immunoregulatory interactions are associated with non-small cell lung cancer survival. American Journal of Cancer Research, 2020, 10, 1770-1784.	1.4	2

#	ARTICLE	IF	CITATIONS
789	Isolation and characterization of cancer stem cells derived from human glioblastoma. <i>American Journal of Cancer Research</i> , 2021, 11, 441-457.	1.4	3
793	Neoadjuvant immunotherapy for resectable non-small cell lung cancer. <i>American Journal of Cancer Research</i> , 2021, 11, 2521-2536.	1.4	2
794	Neoadjuvant immunotherapy facilitates resection of surgically-challenging lung squamous cell cancer. <i>Journal of Thoracic Disease</i> , 2021, 13, 6816-6826.	0.6	6
795	OUP accepted manuscript. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 53-64.	0.6	0
796	Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103538.	2.0	13
797	Genomic instability, inflammatory signaling and response to cancer immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188661.	3.3	56
798	The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. <i>Journal of Thoracic Oncology</i> , 2022, 17, 362-387.	0.5	429
799	Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 752643.	2.2	19
800	Regulation of the Immune Checkpoint Indoleamine 2,3-Dioxygenase Expression by Epstein-Barr Virus. <i>Biomolecules</i> , 2021, 11, 1792.	1.8	4
801	Phase II Study of Nivolumab Plus Ipilimumab with Platinum-Based Chemotherapy for Treatment-Naïve Advanced Non-Small Cell Lung Cancer with Untreated Brain Metastases: Nlke Trial (LOGiK2004). <i>Cancer Management and Research</i> , 2021, Volume 13, 8489-8493.	0.9	4
802	IgA Nephropathy Secondary to Ipilimumab Use. <i>Case Reports in Nephrology and Dialysis</i> , 2022, 11, 327-333.	0.3	3
803	Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges. <i>Frontiers in Oncology</i> , 2021, 11, 771335.	1.3	15
804	Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives. <i>Journal of Modern Oncology</i> , 2021, 23, 428-435.	0.1	0
805	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. <i>Journal of Modern Oncology</i> , 2021, 23, 369-402.	0.1	5
806	CTLA-4 Expression in Tumor-infiltrating Lymphocytes Is Irrelevant to PD-L1 Expression in NSCLC. <i>Anticancer Research</i> , 2021, 41, 6267-6272.	0.5	1
807	Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2985-2994.	1.2	1
808	Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis. <i>Future Oncology</i> , 2022, 18, 883-896.	1.1	3
809	Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients. <i>BMC Cancer</i> , 2021, 21, 1225.	1.1	0

#	ARTICLE	IF	CITATIONS
810	Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, , .	0.7	1
811	The prospect of immunotherapy combined with chemotherapy in patients with advanced non-small cell lung cancer: a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 1703-1703.	0.7	9
812	Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies. <i>Statistics in Medicine</i> , 2021, 40, 6235-6242.	0.8	5
813	ICI Monotherapy or Combination Therapy in the Treatment of NSCLC: How to Choose Among Multiple Options. <i>Japanese Journal of Lung Cancer</i> , 2021, 61, 847-849.	0.0	0
814	TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment. , 2022, 9, e003134.		32
815	NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort. <i>Clinical Lung Cancer</i> , 2022, 23, e90-e98.	1.1	3
816	Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden. <i>Respiratory Research</i> , 2021, 22, 302.	1.4	5
817	Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. <i>Pharmacological Research</i> , 2022, 175, 105997.	3.1	43
818	Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China. <i>Frontiers in Oncology</i> , 2021, 11, 757993.	1.3	23
819	Spatial distribution and functional analysis define the action pathway of Tim-3/Tim-3 ligands in tumor development. <i>Molecular Therapy</i> , 2022, 30, 1135-1148.	3.7	6
820	Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis. <i>BMC Cancer</i> , 2021, 21, 1275.	1.1	6
821	CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 434-445.	0.5	21
822	Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 786046.	2.2	17
823	T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity. <i>Pharmaceuticals</i> , 2021, 14, 1172.	1.7	13
824	Best regimens for treating chemo-naïve incurable squamous non-small cell lung cancer with a programmed death ligand 1 tumor proportion score of 1%–49%: A network meta-analysis. <i>Thoracic Cancer</i> , 2021, , .	0.8	2
825	Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future. <i>Journal of Clinical Medicine</i> , 2021, 10, 5614.	1.0	21
826	Canadian Consensus Recommendations on the Management of MET-Altered NSCLC. <i>Current Oncology</i> , 2021, 28, 4552-4576.	0.9	4
827	Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 5967.	1.7	11

#	ARTICLE	IF	CITATIONS
828	Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation. <i>Journal of Immunology Research</i> , 2021, 2021, 1-18.	0.9	21
829	Phase II Study of the Modified Weekly Nab-paclitaxel Regimen in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 613-618.	0.6	2
830	CheckMate-067: Raising the Bar for the Next Decade in Oncology. <i>Journal of Clinical Oncology</i> , 2022, 40, 111-113.	0.8	8
831	Therapeutic guidance of tumor mutation burden on immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and comprehensive meta-analysis. <i>Journal of the National Cancer Center</i> , 2022, 2, 41-49.	3.0	1
832	Nanoparticles with rough surface improve the therapeutic effect of photothermal immunotherapy against melanoma. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2934-2949.	5.7	22
833	A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 760737.	2.2	8
834	Consolidative durvalumab outcomes in stage III non-small cell lung cancer in a multi-centre study. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100496.	0.7	9
835	Real-World Effectiveness and Prognostic Factors Analysis of Stages I-III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2022, 28, 111-120.	0.3	9
836	Research Progress of PD-1/PD-L1 Inhibitors in Neoimmunoadjuvant Therapy of Esophageal Cancer. <i>Advances in Clinical Medicine</i> , 2021, 11, 5106-5111.	0.0	1
837	A Systematic Analysis of Post-Protocol Therapy in First Line Checkpoint Inhibitor Trials. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
838	Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 113-142.	0.8	5
839	Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy. <i>BMC Cancer</i> , 2022, 22, 46.	1.1	6
840	Biomarkers for predicting the efficacy of immune checkpoint inhibitors. <i>Journal of Cancer</i> , 2022, 13, 481-495.	1.2	12
841	Mitochondria determine response to anti-programmed cell death protein-1 (anti-PD-1) immunotherapy: An evidence-based hypothesis. <i>Mitochondrion</i> , 2022, 62, 151-158.	1.6	26
842	Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 55-63.	0.3	2
843	Precision medicine and the fragmentation of solidarity (and justice). <i>Medicine, Health Care and Philosophy</i> , 2022, 25, 191-206.	0.9	5
844	Association of Smoking Status with Efficacy of First-line Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancers: A Systematic Review and Meta-analysis. <i>Journal of Cancer</i> , 2022, 13, 364-372.	1.2	5
845	Immunotherapy related pericardial effusion on chest CT. <i>Clinical Imaging</i> , 2022, 82, 204-209.	0.8	1

#	ARTICLE	IF	CITATIONS
846	First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology. <i>ESMO Open</i> , 2022, 7, 100355.	2.0	20
847	Lungentumoren: Beinah spektakuläre Erfolge. , 0, , .		0
848	A case of recurrent metastatic tongue cancer with complete response and drug therapy discontinuation after 2 years of nivolumab administration. <i>Journal of Japanese Society of Oral Oncology</i> , 2021, 33, 195-202.	0.0	0
849	Progress in Immunotherapy of Lung Squamous Cell Carcinoma. <i>Advances in Clinical Medicine</i> , 2021, 11, 6054-6060.	0.0	0
850	Perspective on the Immunotherapy of Gastric Cancer. , 2021, , 89-102.		0
851	Adverse events of different PD-1 inhibitors in lung cancer patients: a real-world study. <i>Annals of Translational Medicine</i> , 2022, 10, 183-183.	0.7	7
852	A site-oriented nanosystem for active transcellular chemo-immunotherapy to prevent tumor growth and metastasis. <i>Science China Materials</i> , 2022, 65, 1391-1402.	3.5	6
853	Immunotherapy of cancer in the era of checkpoint inhibitor. <i>Clinical and Experimental Metastasis</i> , 2021, 39, 231.	1.7	1
854	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. <i>Cells</i> , 2022, 11, 320.	1.8	43
855	Immuno-oncology trends: preclinical models, biomarkers, and clinical development. , 2022, 10, e003231.		20
856	An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC). <i>BMC Cancer</i> , 2022, 22, 70.	1.1	2
857	Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. <i>Molecular Cancer</i> , 2022, 21, 28.	7.9	393
858	Clinical Effectiveness And Safety Of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, , .	1.1	2
860	Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. <i>Cancer Cell International</i> , 2022, 22, 2.	1.8	83
861	Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. <i>Journal of Clinical Oncology</i> , 2022, 40, 598-610.	0.8	94
862	Complications following novel therapies for non-small cell lung cancer. <i>Journal of Internal Medicine</i> , 2022, 291, 732-754.	2.7	6
863	Optimal first-line immune checkpoint inhibitor treatment in lung cancer: how to choose?. <i>Future Oncology</i> , 2022, , .	1.1	1
864	Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study. <i>Frontiers in Oncology</i> , 2022, 12, 772076.	1.3	8

#	ARTICLE	IF	CITATIONS
865	Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. , 2022, 10, e003024.		15
866	Safety and effectiveness of ramucirumab and docetaxel: a single-arm, prospective, multicenter, non-interventional, observational, post-marketing safety study of NSCLC in Japan. Expert Opinion on Drug Safety, 2022, 21, 691-698.	1.0	3
867	Inflammatory Thoracic Aortic Aneurysm in a Patient with Advanced Lung Adenocarcinoma Treated with Pembrolizumab. Internal Medicine, 2022, 61, 2339-2341.	0.3	4
868	Comprehensive Analysis of Immune Implication and Prognostic Value of IFI44L in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 798425.	1.3	2
869	Co-occurring genomic alterations and immunotherapy efficacy in NSCLC. Npj Precision Oncology, 2022, 6, 4.	2.3	22
870	Directing hypoxic tumor microenvironment and HIF to illuminate cancer immunotherapy's existing prospects and challenges in drug targets. Current Drug Targets, 2022, 23, .	1.0	2
871	Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study. Investigational New Drugs, 2022, 40, 634-642.	1.2	8
872	Predicting treatment outcomes using ¹⁸ F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110687.	1.4	7
873	Smoking cessation after lung cancer diagnosis improves disease prognosis. Malignant Tumours, 2022, 11, 15-22.	0.1	0
874	Identification of Key Pathways and Genes Related to Immunotherapy Resistance of LUAD Based on WGCNA Analysis. Frontiers in Oncology, 2021, 11, 814014.	1.3	5
875	Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis. Clinical Cancer Research, 2022, 28, 1560-1571.	3.2	33
876	Indirect comparison of pembrolizumab monotherapy versus nivolumab+Ipilimumab in first-line metastatic lung cancer. Immunotherapy, 2022, 14, 295-307.	1.0	3
877	First-Line Immunotherapy for Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2022, 40, 586-597.	0.8	312
878	Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma. Genes and Immunity, 2022, 23, 1-11.	2.2	24
879	Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer. Cancers, 2022, 14, 638.	1.7	16
880	Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab. Japanese Journal of Clinical Oncology, 2022, 52, 479-485.	0.6	8
881	Expression Profiles and Prognostic Value of Multiple Inhibitory Checkpoints in Head and Neck Lymphoepithelioma-Like Carcinoma. Frontiers in Immunology, 2022, 13, 818411.	2.2	1
882	Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. JCO Precision Oncology, 2022, 6, e2100418.	1.5	29

#	ARTICLE	IF	CITATIONS
883	Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 203-213.	1.1	4
884	Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review. <i>Current Oncology</i> , 2022, 29, 479-489.	0.9	6
885	Costâ€ effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan. <i>Future Oncology</i> , 2022, , .	1.1	1
886	A historic cohort study of nutritional status related side effects and weight loss of cancer patients treated with immunotherapy. <i>Clinical Nutrition ESPEN</i> , 2022, 47, 163-169.	0.5	0
887	Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?. <i>Future Oncology</i> , 2022, , .	1.1	4
888	Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2022, 386, 449-462.	13.9	419
889	Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 279-291.	5.1	118
890	First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. <i>Annals of Oncology</i> , 2022, 33, 488-499.	0.6	99
891	Fibroblast-derived LPP as a biomarker for treatment response and therapeutic target in gastric cancer. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 547-560.	2.0	5
892	Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors in NSCLC: Two Heads Are Better Than One. <i>Journal of Thoracic Oncology</i> , 2022, 17, 176-178.	0.5	0
893	The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 170, 103596.	2.0	76
894	Low Programmed Death-Ligand 1â€™Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 392-402.	0.8	87
895	Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC. <i>Cancer Treatment Reviews</i> , 2022, 104, 102350.	3.4	18
896	PD-1 inhibitor causes pathological injury to multiple organs in a Lewis lung cancer mouse model. <i>International Immunopharmacology</i> , 2022, 105, 108551.	1.7	4
897	Adverse events induced by nivolumab and ipilimumab combination regimens. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110583.	1.4	11
898	Association of Personal Characteristics and Effectiveness of Immunotherapy in Late-Stage Non-Small Cell Lung Cancer: A Systematic Review. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	1
899	Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 129-146.	0.9	4
900	First-line nivolumab+ ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients. <i>ESMO Open</i> , 2022, 7, 100394.	2.0	7

#	ARTICLE	IF	CITATIONS
901	First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data. <i>BioDrugs</i> , 2022, 36, 137-151.	2.2	6
902	Post-transplant Malignancies Show Reduced T-cell Abundance and Tertiary Lymphoid Structures as Correlates of Impaired Cancer Immunosurveillance. <i>Clinical Cancer Research</i> , 2022, 28, 1712-1723.	3.2	3
903	CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 771809.	2.2	2
904	Immunotherapy in Lung Cancer: Current Landscape and Future Directions. <i>Frontiers in Immunology</i> , 2022, 13, 823618.	2.2	105
905	A comprehensive evaluation of the safety of ipilimumab, nivolumab and their combination therapy: A systematic review and network meta-analysis. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 557-576.	0.5	0
906	Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0263629.	1.1	11
907	Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2239-2254.	2.0	11
908	Current therapy and development of therapeutic agents for lung cancer. , 2022, 1, 100015.		8
909	Recent advance in nanomaterials for cancer immunotherapy. <i>Chemical Engineering Journal</i> , 2022, 435, 134145.	6.6	16
910	A Novel Immune Classification for Predicting Immunotherapy Responsiveness in Patients With Adamantinomatous Craniopharyngioma. <i>Frontiers in Neurology</i> , 2021, 12, 704130.	1.1	4
911	Efficacy and safety of anti- <i>PD-1</i> in combination with chemotherapy or not as first-line treatment for advanced non-small cell lung cancer: A systematic review and network meta-analysis. <i>Thoracic Cancer</i> , 2022, 13, 322-337.	0.8	13
912	Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature. <i>Immunotherapy</i> , 2021, , .	1.0	3
913	Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management. <i>Frontiers in Immunology</i> , 2021, 12, 800879.	2.2	54
914	Association of Brain Metastases With Immune Checkpoint Inhibitors Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 721760.	1.3	4
915	The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials. <i>Frontiers in Oncology</i> , 2021, 11, 801379.	1.3	21
916	New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2022, 29, 38-55.	0.9	7
918	Identification of drug combinations for lung cancer patients whose tumors are unresponsive to targeted therapy: clinical bases and future directions. <i>Expert Review of Precision Medicine and Drug Development</i> , 2022, 7, 29-38.	0.4	0
919	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. <i>Immune Network</i> , 2022, 22, e2.	1.6	53

#	ARTICLE	IF	CITATIONS
921	Neurological complications of lung cancer. , 2022, , 243-276.		0
922	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. <i>Experientia Supplementum</i> (2012), 2022, 113, 295-350.	0.5	3
924	Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer. <i>Cancer Control</i> , 2022, 29, 107327482210766.	0.7	11
925	Combination immunotherapy of nivolumab plus ipilimumab in a lung cancer patient with Werner syndrome; a case report. <i>Respiratory Medicine Case Reports</i> , 2022, 37, 101642.	0.2	1
927	Patient-Reported Outcomes During Checkpoint Inhibition: Insight into Symptom Burden in Daily Clinical Practice. <i>Journal of Pain and Symptom Management</i> , 2022, 63, 997-1005.	0.6	5
928	Diabetic ketoacidosis shortly after COVID-19 vaccination in a non-small cell lung cancer patient receiving combination of PD-1 and CTLA-4 inhibitors: A case report. <i>Thoracic Cancer</i> , 2022, 13, 1220-1223.	0.8	10
929	The treatment of advanced pulmonary sarcomatoid carcinoma. <i>Future Oncology</i> , 2022, 18, 727-738.	1.1	5
930	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA. <i>International Journal of Clinical Oncology</i> , 2022, 27, 695-706.	1.0	11
931	Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data. <i>Annals of Oncology</i> , 2022, 33, 511-521.	0.6	36
932	The New Era of Immunotherapy in Gastric Cancer. <i>Cancers</i> , 2022, 14, 1054.	1.7	68
933	Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC. , 2022, 10, e004064.		10
934	Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Study. <i>Frontiers in Oncology</i> , 2022, 12, 820302.	1.3	12
935	Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2405-2420.	2.0	10
937	Advances in Neoadjuvant and Adjuvant Immunotherapy and Targeted Therapy for Resectable NSCLC (CME article). <i>International Journal of Cancer Care and Delivery</i> , 2022, 2, .	0.0	0
938	Adverse effects of combination immunotherapy in renal cancer, lung cancer, and melanoma. <i>Onkologie (Czech Republic)</i> , 2022, 16, 10-15.	0.0	0
939	Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors. <i>International Journal of Radiation Oncology Biology Physics</i> . 2022. 114. 60-74.	0.4	33
940	High Intensity Aerobic exercise training and Immune cell Mobilization in patients with lung cancer (HI) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.1	10
941	Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?. <i>Cancers</i> , 2022, 14, 1710.	1.7	13

#	ARTICLE	IF	CITATIONS
942	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 499-514.	1.1	7
943	Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2847.	1.8	19
944	Neutrophil Extracellular Traps in Cancer Therapy Resistance. <i>Cancers</i> , 2022, 14, 1359.	1.7	30
945	A Bayesian Network Meta-Analysis of First-Line Treatments for Non-Small Cell Lung Cancer with High Programmed Death Ligand-1 Expression. <i>Journal of Clinical Medicine</i> , 2022, 11, 1492.	1.0	3
946	The evolutionary legacy of immune checkpoint inhibitors. <i>Seminars in Cancer Biology</i> , 2022, 86, 491-498.	4.3	37
947	Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. <i>European Journal of Cancer</i> , 2022, 164, 95-104.	1.3	0
948	Current Status of Monoclonal Antibodies-Based Therapies in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Cureus</i> , 2022, 14, e22942.	0.2	2
949	Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis. <i>BMC Cancer</i> , 2022, 22, 255.	1.1	11
950	Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?. <i>British Journal of Cancer</i> , 2022, 127, 383-393.	2.9	36
951	The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer. <i>Biomarker Research</i> , 2022, 10, 9.	2.8	28
952	A Systematic Review of the Mechanisms Involved in Immune Checkpoint Inhibitors Cardiotoxicity and Challenges to Improve Clinical Safety. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 851032.	1.8	14
953	Targeting Cancer Cell Ferroptosis to Reverse Immune Checkpoint Inhibitor Therapy Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 818453.	1.8	14
954	Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100312.	0.6	7
955	Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 1855.	1.0	11
956	Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma. <i>Biomedicines</i> , 2022, 10, 673.	1.4	4
957	Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216). <i>JAMA Oncology</i> , 2022, 8, 717.	3.4	32
958	Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. <i>Nature</i> , 2022, 603, 942-948.	13.7	156
959	Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy. <i>Cancers</i> , 2022, 14, 1580.	1.7	17

#	ARTICLE	IF	CITATIONS
960	Immunotherapy for a POLE Mutation Advanced Non-Small-Cell Lung Cancer Patient. <i>Frontiers in Pharmacology</i> , 2022, 13, 817265.	1.6	5
961	Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function. <i>Frontiers in Oncology</i> , 2022, 12, 836859.	1.3	25
962	Rethinking the Status of Chemotherapy Combined With the Addition of Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibition and Programmed Death 1 or Programmed Death-Ligand 1 Blockade. <i>Journal of Thoracic Oncology</i> , 2022, 17, 341-344.	0.5	0
963	dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score $\geq 50\%$. <i>Clinical Lung Cancer</i> , 2022, 23, 122-134.	1.1	8
964	Case Report: Neuromyelitis Optica After Treatment of Uveal Melanoma With Nivolumab and Ipilimumab. <i>Frontiers in Oncology</i> , 2022, 12, 806501.	1.3	10
965	Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1916-1928.	0.8	94
967	Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience. <i>Diagnostics</i> , 2022, 12, 685.	1.3	1
968	Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study. <i>Cancer Medicine</i> , 2022, 11, 3074-3083.	1.3	16
969	Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 1404.	1.7	63
970	Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 762-771.	0.8	71
971	What Is Long-Term Survival and Which First-Line Immunotherapy Brings Long-Term Survival for Advanced Wild-Type Non-Small Cell Lung Cancer: A Network Meta-Analysis Based on Integrated Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 764643.	2.2	3
972	Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial. <i>BMJ Open</i> , 2022, 12, e059779.	0.8	1
973	KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves. <i>BMC Medical Research Methodology</i> , 2022, 22, 93.	1.4	9
974	Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC. <i>Frontiers in Immunology</i> , 2022, 13, 828560.	2.2	18
975	Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer. <i>ESMO Open</i> , 2022, 7, 100445.	2.0	26
976	Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review. <i>Academic Radiology</i> , 2022, 29, 1869-1884.	1.3	3
977	Characterization of the immune cell infiltration landscape in lung adenocarcinoma. <i>Archives of Biochemistry and Biophysics</i> , 2022, 721, 109168.	1.4	0
978	Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Translational Oncology</i> , 2022, 19, 101383.	1.7	4

#	ARTICLE	IF	CITATIONS
979	Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: A systematic review and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 173, 103660.	2.0	4
980	Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives. <i>Cancers</i> , 2022, 14, 122.	1.7	16
981	Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13311.	1.8	54
982	Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 75.	1.7	3
983	Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 245.	1.8	6
984	Application of the Plan-Do-Check-Act Cycle for Managing Immune-Related Adverse Events. <i>Journal of Analytical Oncology</i> , 0, 10, 61-68.	0.1	0
985	Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer. , 2021, 9, e002780.		15
986	Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy. <i>BMC Pulmonary Medicine</i> , 2021, 21, 409.	0.8	9
987	What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?. <i>Frontiers in Immunology</i> , 2021, 12, 773168.	2.2	18
988	First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. <i>Frontiers in Oncology</i> , 2021, 11, 771045.	1.3	20
989	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. <i>Cancers</i> , 2022, 14, 109.	1.7	21
990	Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. <i>MedComm</i> , 2021, 2, 692-729.	3.1	38
991	Macrophage Polarity and Disease Control. <i>International Journal of Molecular Sciences</i> , 2022, 23, 144.	1.8	80
992	Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 353-360.	0.8	9
993	Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 760686.	1.3	8
994	Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events. <i>Clinical Cancer Research</i> , 2022, 28, 1250-1257.	3.2	11
995	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 509-528.	21.5	201
996	E-cadherin on epithelial-mesenchymal transition in thyroid cancer. <i>Cancer Cell International</i> , 2021, 21, 695.	1.8	12

#	ARTICLE	IF	CITATIONS
997	A case of haemoptysis and bilateral areas of lung consolidation sparing the right lower lobe. <i>Breathe</i> , 2021, 17, 210072.	0.6	0
998	Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 777686.	1.3	5
999	Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2021, 12, 1182-1192.	0.9	3
1000	A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Translational Lung Cancer Research</i> , 2021, 10, 4511-4525.	1.3	6
1001	Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1 ^{low} and immune desert-like mouse tumors. <i>Oncology Reports</i> , 2021, 47, .	1.2	10
1002	Comprehensive Analysis of the Immunogeomic Landscape and Clinical Features in Cervical Cancer. , 2021, , .		0
1003	Developments in systemic therapies for the management of lung cancer. <i>Internal Medicine Journal</i> , 2021, 51, 2012-2020.	0.5	2
1004	Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model. <i>JAMA Network Open</i> , 2021, 4, e2139573.	2.8	8
1005	Bone metastases in non-small cell lung cancer: a narrative review. <i>Journal of Thoracic Disease</i> , 2022, 14, 1696-1712.	0.6	11
1006	Autoimmunity regulation within the tumor microenvironment. , 2022, , 51-71.		0
1007	Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 2657-2668.	3.2	4
1008	The use of immunotherapy in older patients with advanced non-small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2022, 106, 102394.	3.4	16
1009	The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis. <i>Investigational New Drugs</i> , 2022, 40, 810-817.	1.2	5
1010	Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features. <i>Frontiers in Immunology</i> , 2022, 13, 875093.	2.2	10
1011	The Landscape of Immunotherapy Resistance in NSCLC. <i>Frontiers in Oncology</i> , 2022, 12, 817548.	1.3	27
1012	Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases. <i>Frontiers in Oncology</i> , 2022, 12, 787080.	1.3	1
1013	Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. <i>Nature Medicine</i> , 2022, 28, 939-945.	15.2	75
1014	Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 862084.	2.2	18

#	ARTICLE	IF	CITATIONS
1015	Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives. <i>Frontiers in Pharmacology</i> , 2022, 13, 875330.	1.6	4
1016	Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. , 2022, 10, e004424.		54
1017	Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer. <i>Translational Oncology</i> , 2022, 20, 101418.	1.7	3
1018	Therapeutic approaches for the treatment of head and neck squamous cell carcinomaâ€“An update on clinical trials. <i>Translational Oncology</i> , 2022, 21, 101426.	1.7	33
1049	Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer. <i>Archives of Pharmacal Research</i> , 2022, 45, 263-279.	2.7	11
1050	Fangchinoline induces gallbladder cancer cell apoptosis by suppressing PI3K/Akt/XIAP axis. <i>PLoS ONE</i> , 2022, 17, e0266738.	1.1	2
1057	Updates on clinical trials for the management of hepatocellular carcinoma. , 2022, , 259-273.		0
1058	Immunotherapy for hepatocellular cancer: a review of current status. , 2022, , 245-258.		0
1059	Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases. <i>Oncologist</i> , 2022, 27, 839-848.	1.9	18
1060	Phase 2 study of firstâ€“line pembrolizumab monotherapy in elderly patients with nonâ€“smallâ€“cell lung cancer expressing high <sc>PDâ€“L1 </sc>. <i>Thoracic Cancer</i> , 2022, 13, 1611-1618.	0.8	4
1061	Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model. <i>Frontiers in Immunology</i> , 2022, 13, 829634.	2.2	7
1062	Radiotherapy and Immunotherapy: The Power of the Teamwork for the Treatment of NSCLC. <i>Anticancer Research</i> , 2022, 42, 2241-2247.	0.5	6
1063	HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients. <i>Cancers</i> , 2022, 14, 2260.	1.7	5
1064	A Novel Risk Score Model Based on Eleven Extracellular Matrix-Related Genes for Predicting Overall Survival of Glioma Patients. <i>Journal of Oncology</i> , 2022, 2022, 1-20.	0.6	3
1065	Pyroptosis-Related Patterns Predict Tumor Immune Landscape and Immunotherapy Response in Bladder Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 815290.	1.6	2
1066	Combination of interventional oncology local therapies and immunotherapy for the treatment of hepatocellular carcinoma. <i>Journal of Liver Cancer</i> , 2022, 22, 93-102.	0.3	6
1068	Real-world data on the incidence of immune-related adverse events associated with anti-PD-1/PD-L1 treatment in Russia. <i>Voprosy Onkologii</i> , 2022, 68, 188-199.	0.1	3
1069	Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	3

#	ARTICLE	IF	CITATIONS
1070	Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study. <i>Cancers</i> , 2022, 14, 2276.	1.7	4
1071	Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5097.	1.8	3
1072	Real-world clinical practice for advanced non-small-cell lung cancer in the very elderly: A retrospective multicenter analysis. <i>Clinical Lung Cancer</i> , 2022, 23, 532-541.	1.1	2
1074	Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 781-792.	5.1	150
1075	Combination Immunotherapy in the First-line Setting for Non-small-cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2022, 62, 75-80.	0.0	0
1076	An optimal portfolio of photothermal combined immunotherapy. <i>Cell Reports Physical Science</i> , 2022, 3, 100898.	2.8	22
1077	The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	3
1078	An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, 8230.	1.6	9
1079	Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy. <i>BMJ Open</i> , 2022, 12, e050112.	0.8	6
1080	In vitro preliminary study on different anti-PD-1 antibody concentrations on T cells activation. <i>Scientific Reports</i> , 2022, 12, 8370.	1.6	0
1081	Prolonged response to checkpoint inhibitor therapy in two metastatic mucoepidermoid salivary gland carcinoma cases: a research report.. <i>Cold Spring Harbor Molecular Case Studies</i> , 2022, 8, .	0.7	3
1082	Development of a LAG-3 immunohistochemistry assay for melanoma. <i>Journal of Clinical Pathology</i> , 2023, 76, 591-598.	1.0	5
1084	Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head&neck cancer. <i>Cancer Medicine</i> , 2022, 11, 2550-2560.	1.3	25
1085	Changing the Drug Development and Therapeutic Paradigm with Biologic Drug Combinations and Bispecifics: How to Choose Between These Two Approaches?. <i>Clinical and Translational Science</i> , 0, , .	1.5	2
1086	Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
1087	The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	13
1088	Monitoring and Management of the Patient with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Current Perspectives. <i>Journal of Inflammation Research</i> , 0, Volume 15, 3105-3118.	1.6	6
1089	A phase II clinical trial of combination nivolumab, ipilimumab, and paclitaxel in patients with untreated metastatic non-small cell lung cancer: The OPTIMAL Trial. <i>JTO Clinical and Research Reports</i> , 2022, , 100337.	0.6	0

#	ARTICLE	IF	CITATIONS
1090	Comparative safety of immune checkpoint inhibitors and chemotherapy in advanced non-small cell lung cancer: A systematic review and network meta-analysis. <i>International Immunopharmacology</i> , 2022, 108, 108848.	1.7	5
1091	HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors. <i>Lung Cancer</i> , 2022, 170, 1-10.	0.9	14
1093	Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
1094	Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	27
1095	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. , 2022, 10, e003956.		16
1096	Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	12
1097	Lung Inflammation Predictors in Combined Immune Checkpoint-Inhibitor and Radiation Therapyâ€™ Proof-of-Concept Animal Study. <i>Biomedicines</i> , 2022, 10, 1173.	1.4	3
1098	Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	19
1099	Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	12
1100	Relationship between Patientsâ€™ Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-14.	0.6	2
1101	Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 3071-3085.	2.0	5
1102	Chemo and Immuno-Therapeutic Options for Nonsmall Cell Lung Cancer Lung Cancer. <i>Surgical Clinics of North America</i> , 2022, 102, 493-498.	0.5	1
1104	VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment. <i>International Journal of Biological Sciences</i> , 2022, 18, 3845-3858.	2.6	64
1106	PD-1/L1 With or Without CTLA-4 Inhibitors Versus Chemotherapy in Advanced Non-Small Cell Lung Cancer. <i>Cancer Control</i> , 2022, 29, 107327482211075.	0.7	1
1107	Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. , 2022, 10, e004688.		34
1108	The advanced development of molecular targeted therapy for hepatocellular carcinoma. <i>Cancer Biology and Medicine</i> , 2022, 19, 1-16.	1.4	18
1109	High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	7
1110	First-line chemoimmunotherapy versus chemotherapy in PD-L1-negative patients with non-small-cell lung cancer. <i>Immunotherapy</i> , 2022, 14, 871-877.	1.0	1

#	ARTICLE	IF	CITATIONS
1111	Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1104-1120.	1.3	7
1112	Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1755-1763.	1.2	5
1113	Population Pharmacokinetics of Nivolumab in Japanese Patients with Non-Small Cell Lung Cancer. <i>Therapeutic Drug Monitoring</i> , 2022, Publish Ahead of Print, .	1.0	0
1114	Blood Biomarkers of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 3245.	1.0	8
1115	Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 645-654.	0.4	10
1116	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 529-540.	21.5	134
1117	Vascular endothelial growth factor receptor 2 expression and immunotherapy efficacy in non-small cell lung cancer. <i>Cancer Science</i> , 0, , .	1.7	1
1118	Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	13
1119	Emerging Therapies in Penile Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1120	Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
1121	Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	21
1122	Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 759-771.	1.3	1
1123	Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-Small Cell Lung Cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
1124	Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	15
1125	Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review. <i>Thorax</i> , 2022, 77, 1163-1174.	2.7	5
1126	Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung. <i>Clinical Lung Cancer</i> , 2022, 23, 457-466.	1.1	12
1127	Inibidores de checkpoints imunolgicos no tratamento de cncer de pulmo de clulas no pequenas (NSCLC). <i>Revista Brasileira De Cincias Biomdicas</i> , 2022, 3, E0632022.	0.1	0
1128	Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2

#	ARTICLE	IF	CITATIONS
1129	Correlations between Objective Response Rate and Survival-based Endpoints in First-line Advanced Non-Small Cell Lung Cancer: a Systematic Review and Meta-analysis. <i>Lung Cancer</i> , 2022, , .	0.9	5
1130	Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates. <i>Cancer Management and Research</i> , 0, Volume 14, 2079-2090.	0.9	3
1131	Contribution of the Skin-Gut Axis to Immune-Related Adverse Events with Multi-System Involvement. <i>Cancers</i> , 2022, 14, 2995.	1.7	5
1133	Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States. <i>Journal of Medical Economics</i> , 2022, 25, 660-668.	1.0	3
1134	Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States. <i>Journal of Medical Economics</i> , 2022, 25, 703-711.	1.0	2
1135	Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211117.	1.4	12
1136	Immunotherapy: an alternative promising therapeutic approach against cancers. <i>Molecular Biology Reports</i> , 2022, 49, 9903-9913.	1.0	17
1137	Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel. <i>Investigational New Drugs</i> , 0, , .	1.2	0
1138	Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan. <i>Clinical Drug Investigation</i> , 2022, 42, 599-609.	1.1	4
1139	Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?. <i>Journal of Immunotherapy</i> , 0, Publish Ahead of Print, .	1.2	0
1140	Artificial intelligence-derived gut microbiome as a predictive biomarker for therapeutic response to immunotherapy in lung cancer: protocol for a multicentre, prospective, observational study. <i>BMJ Open</i> , 2022, 12, e061674.	0.8	4
1141	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. <i>Nature Cancer</i> , 2022, 3, 665-680.	5.7	18
1142	Multiplex Immunofluorescence and the Digital Image Analysis Workflow for Evaluation of the Tumor Immune Environment in Translational Research. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	12
1143	Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study. <i>Translational Lung Cancer Research</i> , 2022, 11, 1038-1050.	1.3	4
1144	A Metabolism-Related Gene Prognostic Index Bridging Metabolic Signatures and Antitumor Immune Cycling in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
1145	Emerging insights on immunotherapy in liver cancer. <i>Antioxidants and Redox Signaling</i> , 0, , .	2.5	4
1146	PET Imaging of Lung Cancers in Precision Medicine: Current Landscape and Future Perspective. <i>Molecular Pharmaceutics</i> , 2022, 19, 3471-3483.	2.3	4
1147	Dissecting the ferroptosis-related prognostic biomarker and immune microenvironment of driver gene-negative lung cancer. <i>Experimental Biology and Medicine</i> , 2022, 247, 1447-1465.	1.1	1

#	ARTICLE	IF	CITATIONS
1148	Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1993-2008.	1.2	5
1149	Tumor immunotherapy: Mechanisms and clinical applications. , 2022, 1, .		2
1150	Immunotherapy in NSCLC Patients with Brain Metastases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7068.	1.8	12
1151	Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	23
1152	A Case of Primary Lung Adenocarcinoma due to Bilateral Adrenal Metastases with Addison's Disease as the Initial Symptom. <i>Japanese Journal of Lung Cancer</i> , 2022, 62, 216-220.	0.0	0
1154	Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	14
1155	Non-small cell lung cancer in the era of immunotherapy. <i>Seminars in Oncology</i> , 2022, 49, 337-343.	0.8	1
1156	Advanced non-small-cell lung cancer: how to manage non-oncogene disease. <i>Drugs in Context</i> , 0, 11, 1-14.	1.0	2
1157	Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-27.	0.6	5
1158	Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab. <i>Modern Pathology</i> , 2022, 35, 1529-1539.	2.9	14
1159	Clinically-meaningful improvements in therapy for unresectable NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 927-937.	1.1	6
1160	Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 861-874.	1.1	6
1161	Nivolumab plus ipilimumab in malignant pleural mesothelioma. <i>Expert Review of Anticancer Therapy</i> , 0, , .	1.1	1
1162	The oligometastatic spectrum in the era of improved detection and modern systemic therapy. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 585-599.	12.5	39
1163	Mechanisms of resistance to immune checkpoint inhibitors. <i>Cancer Science</i> , 2022, 113, 3303-3312.	1.7	12
1164	The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7839.	1.8	13
1165	Soluble Immune Checkpoint-Related Proteins in Blood Are Associated With Invasion and Progression in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
1166	Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , 2022, 52, .	1.7	7

#	ARTICLE	IF	CITATIONS
1167	Immunosenescence, inflammaging, and cancer immunotherapy efficacy. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 915-926.	1.1	12
1168	New Implications of Patients'™ Sex in Today's™ Lung Cancer Management. <i>Cancers</i> , 2022, 14, 3399.	1.7	1
1169	Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors. <i>Immunotherapy</i> , 2022, 14, 927-944.	1.0	7
1170	Camrelizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: Treatment response, survival pattern, and safety. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 1775-1782.	0.7	2
1171	Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
1172	Cell-by-Cell: Unlocking Lung Cancer Pathogenesis. <i>Cancers</i> , 2022, 14, 3424.	1.7	3
1173	Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes. <i>Cancers</i> , 2022, 14, 3472.	1.7	1
1174	The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
1176	The Challenges of Novel Therapies in the Care of the Critically Ill Cancer Patient. , 2023, , 448-458.		0
1177	The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 347-366.	2.7	11
1178	Immunotherapy-induced Hepatotoxicity: A Review. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	3
1179	A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 29, 413-425.	2.3	9
1180	Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	13
1181	Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors. <i>Hormone and Metabolic Research</i> , 2022, 54, 795-812.	0.7	1
1182	Immunotherapy of Lung Cancer. <i>Medical Radiology</i> , 2022, , .	0.0	29
1183	Analysis of the Correlation between Immunogenomic Phenotype and Patient Outcomes in Prostate Cancer. , 2022, , .		0
1184	Older Patients with Lung Cancer: a Summary of Seminal Contributions to Optimal Patient Care. <i>Current Oncology Reports</i> , 2022, 24, 1607-1618.	1.8	1
1185	Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3709-3719.	3.2	9

#	ARTICLE	IF	CITATIONS
1186	Benchmarking bioinformatics approaches for tumour mutational burden evaluation from a large cancer panel against whole-exome sequencing. <i>Journal of Clinical Pathology</i> , 2023, 76, 276-280.	1.0	1
1187	Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies. <i>JCO Precision Oncology</i> , 2022, , .	1.5	0
1188	Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study. <i>Cancers</i> , 2022, 14, 3878.	1.7	7
1189	Pulmonary Lymphangitis Carcinomatosa Mimicking Immunotherapy-Related Interstitial Pneumonitis: A Case Report. <i>Case Reports in Oncology</i> , 0, , 732-737.	0.3	0
1190	Immunotherapy in non-small cell lung cancer: Past, present, and future directions. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	32
1191	Long-term benefits of combined immunotherapy over chemotherapy in non-small cell lung cancer. , 0, .		0
1192	The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 4523.	1.0	7
1193	Associations of influenza vaccination with severity of immune-related adverse events in patients with advanced thoracic cancers on immune checkpoint inhibitors. <i>ERJ Open Research</i> , 0, , 00684-2021.	1.1	0
1194	Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1195	Camrelizumab in patients with advanced non-squamous non-small cell lung cancer: a cost-effective analysis in China. <i>BMJ Open</i> , 2022, 12, e061592.	0.8	2
1196	Analytical Principles of Cancer Next Generation Sequencing. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 395-408.	0.7	3
1197	Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment. <i>JAMA Network Open</i> , 2022, 5, e2227211.	2.8	8
1198	Immune-based combination therapy to convert immunologically cold tumors into hot–tumors: an update and new insights. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 288-307.	2.8	14
1199	Pathological Responses of the Primary Tumor and Locoregional Lymph Nodes After Neoadjuvant Immunochemotherapy in Esophageal Squamous Cell Cancer. <i>World Journal of Oncology</i> , 2022, 13, 195-204.	0.6	2
1200	Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
1201	Live Biotherapeutic <i>Lactococcus lactis</i> GEN3013 Enhances Antitumor Efficacy of Cancer Treatment via Modulation of Cancer Progression and Immune System. <i>Cancers</i> , 2022, 14, 4083.	1.7	7
1202	Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1203	Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12

#	ARTICLE	IF	CITATIONS
1204	Advances in the Treatment of Postoperative Recurrence of Non-Small Cell Lung Cancer and Their Impact on Survival in Asian Patients. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, , .	0.4	1
1205	Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. <i>Genes and Diseases</i> , 2023, 10, 960-989.	1.5	13
1206	Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1207	Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1208	Phase 1 Study of Chemoradiotherapy Combined with Nivolumab±Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2022, 82, 518-526.	0.9	12
1209	Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1210	Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. <i>Nature Medicine</i> , 2022, 28, 1831-1839.	15.2	47
1211	Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. <i>Cancer Cell</i> , 2022, 40, 1010-1026.e11.	7.7	47
1212	A novel chemokine-based signature for prediction of prognosis and therapeutic response in glioma. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 2090-2103.	1.9	9
1213	Medical management of older patients with lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	1
1214	Adverse Events Induced by Nivolumab Plus Ipilimumab vs. Nivolumab Monotherapy among Cancer Patients: A Systematic Review and Meta-Analysis. <i>Cancer Investigation</i> , 2022, 40, 777-788.	0.6	1
1215	Occurrence of hyperprogressive disease following administration of immune checkpoint inhibitors in lung squamous cell carcinoma: A case report. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	0
1216	Targeting KRAS: Crossroads of Signaling and Immune Inhibition. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022, 5, 68-78.	0.6	6
1217	Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the field. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1218	Novel approaches for treatment of endometrial carcinoma. <i>Current Problems in Cancer</i> , 2022, 46, 100895.	1.0	7
1220	Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 179, 103806.	2.0	14
1221	A risk stratification model for toxicities in phase 1 immunotherapy trials. <i>European Journal of Cancer</i> , 2022, 175, 11-18.	1.3	0
1222	Construction of functionalized ruthenium-modified selenium coated with pH-responsive silk fibroin nanomaterials enhanced anticancer efficacy in hepatocellular cancer. <i>Process Biochemistry</i> , 2022, 122, 203-213.	1.8	1

#	ARTICLE	IF	CITATIONS
1223	Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review. <i>European Journal of Cancer</i> , 2022, 175, 60-76.	1.3	12
1224	Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy. <i>Internal Medicine</i> , 2023, 62, 1319-1322.	0.3	3
1225	Diagnostic Applications of Nuclear Medicine: Lung and Mediastinal Tumors. , 2022, , 743-809.		0
1226	Checkpoint Inhibitors in Non-small Cell Lung Cancer: Potentials and Challenges. , 2022, , .		0
1227	Immunotherapy in Early Stage Non-Small Cell Lung Cancer. <i>Advances in Lung Cancer (Irvine)</i> , 2022, 11, 31-44.	0.2	0
1229	Available Immunotherapy Drugs in Oncology. <i>Current Clinical Pathology</i> , 2022, , 5-23.	0.0	0
1230	Safety Profile of Mutant EGFR-TK Inhibitors in Advanced Non-“Small Cell Lung Cancer: A Meta-analysis. , 2022, , .		0
1231	On the Immunotherapy for Tumors. <i>Science Insights</i> , 2022, 41, 611-617.	0.1	0
1232	A David and Goliath set-up: a qualitative study of the challenges of ensuring the introduction of cost-effective new cancer medicines in Finland. <i>Journal of Pharmaceutical Policy and Practice</i> , 2022, 15, .	1.1	0
1233	Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients. <i>Oncolmmunology</i> , 2022, 11, .	2.1	6
1234	Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival Benefit. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1365-1374.	0.5	0
1235	Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer. <i>Current Oncology</i> , 2022, 29, 6260-6276.	0.9	6
1236	Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. <i>Nature Cancer</i> , 2022, 3, 1151-1164.	5.7	79
1237	Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. <i>Journal of Thoracic Oncology</i> , 2023, 18, 79-92.	0.5	11
1238	Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. <i>Cancer Cell</i> , 2022, 40, 1161-1172.e5.	7.7	44
1239	Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1240	Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1241	Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series. <i>Oncology Letters</i> , 2022, 24, .	0.8	1

#	ARTICLE	IF	CITATIONS
1242	Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies. <i>JCO Precision Oncology</i> , 2022, , .	1.5	0
1243	Benefits from Adjuvant Chemotherapy in Patients with Resected Non-Small Cell Lung Cancer: Possibility of Stratification by Gene Amplification of ACTN4 According to Evaluation of Metastatic Ability. <i>Cancers</i> , 2022, 14, 4363.	1.7	2
1244	Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance. <i>Cancers</i> , 2022, 14, 4562.	1.7	15
1245	Biomarkers for immune checkpoint inhibitors in solid tumors. <i>Clinical and Translational Oncology</i> , 2023, 25, 126-136.	1.2	3
1246	Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>British Journal of Cancer</i> , 2022, 127, 2034-2042.	2.9	8
1247	A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100416.	0.6	1
1248	Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1335-1354.	0.5	40
1249	Clinical predictive value of naïve and memory T cells in advanced NSCLC. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
1250	Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1251	Immune checkpoint inhibitors for non-small cell lung cancer patients on steroid or non-steroidal anti-inflammatory drugs treatment—therapeutic indication or therapeutic efficacy?. <i>Translational Cancer Research</i> , 2022, 11, 3003-3005.	0.4	0
1252	Immunopeptidome Diversity in Chronic Lymphocytic Leukemia Identifies Patients with Favorable Disease Outcome. <i>Cancers</i> , 2022, 14, 4659.	1.7	1
1253	Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
1254	Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer. , 2022, 10, e005128.		4
1255	Sex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis. <i>Annals of Medicine</i> , 2022, 54, 2605-2615.	1.5	7
1256	Evaluating the Combined Anticancer Response of Checkpoint Inhibitor Immunotherapy and FAP-Targeted Molecular Radiotherapy in Murine Models of Melanoma and Lung Cancer. <i>Cancers</i> , 2022, 14, 4575.	1.7	5
1257	N6-Methyladenosine (m6A)-Related lncRNAs Are Potential Signatures for Predicting Prognosis and Immune Response in Lung Squamous Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-13.	0.6	1
1258	Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2235-2242.	1.2	4
1259	Combination of Tumor Mutational Burden and DNA Damage Repair Gene Mutations with Stromal/Immune Scores Improved Prognosis Stratification in Patients with Lung Adenocarcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	2

#	ARTICLE	IF	CITATIONS
1260	Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 202-213.	0.4	25
1261	The influence of baseline characteristics on the efficacy of immune checkpoint inhibitors for advanced lung cancer: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
1262	Severe eosinophilia and subsequent dermatologic immune-related adverse event with squamous cell carcinoma antigen elevation induced by nivolumab and ipilimumab. <i>Respirology Case Reports</i> , 2022, 10, .	0.3	1
1263	Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 5136-5148.	3.2	8
1264	International consensus on radiotherapy in metastatic non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 1763-1795.	1.3	10
1265	Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1266	Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: A real-world analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1267	Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 0, , .	1.3	3
1268	Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors. <i>Biomedicines</i> , 2022, 10, 2211.	1.4	2
1269	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
1270	DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	6
1271	What's Current and What's New in Mesothelioma?. <i>Clinical Oncology</i> , 2022, 34, 771-780.	0.6	2
1272	Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. <i>Lancet</i> , The, 2022, 400, 1008-1019.	6.3	48
1273	Is immunotherapy at reduced dose and radiotherapy for older patients with locally advanced non-small lung cancer feasible?" a narrative review by the international geriatric radiotherapy group. <i>Translational Cancer Research</i> , 2022, 11, 3298-3308.	0.4	2
1274	Bacterial outer membrane vesicle-based cancer nanovaccines. <i>Cancer Biology and Medicine</i> , 2022, 19, 1290-1300.	1.4	14
1275	First-in-human study of ONO4578, an antagonist of prostaglandin receptor 4, alone and with nivolumab in solid tumors. <i>Cancer Science</i> , 2023, 114, 211-220.	1.7	4
1276	Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2022, 177, 175-185.	1.3	106
1277	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	33

#	ARTICLE	IF	CITATIONS
1278	Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 289-300.	1.0	5
1279	Detecting monocyte trafficking in an animal model of glioblastoma using R2* and quantitative susceptibility mapping. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 733-742.	2.0	2
1280	End-of-life impact of concurrent diabetes mellitus and adrenal insufficiency as immune-related adverse events in an advanced non-small cell lung cancer patient. <i>Thoracic Cancer</i> , 0, , .	0.8	2
1281	A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412. <i>Clinical Cancer Research</i> , 2022, 28, 5088-5097.	3.2	12
1282	Efficacy and safety of nivolumab for advanced/recurrent non-small-cell lung cancer: an up-to-date meta-analysis of large-scale phase III randomized controlled trials. <i>Future Oncology</i> , 2022, 18, 3667-3675.	1.1	3
1284	<i>Cancer Immunotherapy Clinical Trials</i> , 2022, , 1-24.		0
1285	NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC. <i>Journal of Thoracic Oncology</i> , 2023, 18, 106-119.	0.5	21
1287	Current status of immunotherapy for non-small cell lung cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	11
1288	History and Evidence of Immune Checkpoint Inhibitors in the Respiratory Field. <i>Nihon Kikan Shokudoka Gakkai Kaiho</i> , 2022, 73, 325-331.	0.0	0
1289	Treatment-related adverse events of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: a meta-analysis. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2022, 50, 301-309.	1.9	2
1290	Ethanol Extract of <i>Ocimum sanctum</i> Linn. Inhibits Cell Migration of Human Lung Adenocarcinoma Cells (A549) by Downregulation of Integrin $\alpha 2 \beta 3$, $\alpha 5 \beta 1$, and VEGF. <i>Scientia Pharmaceutica</i> , 2022, 90, 69.	0.7	0
1292	Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100423.	0.6	1
1293	BFAST but be smart: bTMB remains an exploratory biomarker in NSCLC. <i>Nature Reviews Clinical Oncology</i> , 0, , .	12.5	0
1296	Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1297	Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
1298	Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CT. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
1299	Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers. <i>Cancers</i> , 2022, 14, 4985.	1.7	5
1300	Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy. <i>Acta Biomaterialia</i> , 2022, 154, 401-411.	4.1	3

#	ARTICLE	IF	CITATIONS
1302	Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. <i>Journal of Clinical Oncology</i> , 2023, 41, 1200-1212.	0.8	75
1303	Biomarker-Targeted Therapies in Non-Small Cell Lung Cancer: Current Status and Perspectives. <i>Cells</i> , 2022, 11, 3200.	1.8	15
1304	Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1305	LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials. <i>Cancers</i> , 2022, 14, 4975.	1.7	9
1306	Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer?. <i>Cancers</i> , 2022, 14, 4861.	1.7	1
1307	A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1311	Adverse events of immune checkpoint inhibitors for patients with digestive system cancers: A systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1312	First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations. <i>Journal of Thoracic Oncology</i> , 2023, 18, 204-222.	0.5	29
1313	A Case of Pseudo-progression-like Pleurisy After Combined Treatment with Nivolumab and Ipilimumab for Lung Adenocarcinoma. <i>Japanese Journal of Lung Cancer</i> , 2022, 62, 400-405.	0.0	1
1314	Effectiveness of immunological agents in non-small cell lung cancer. <i>Cancer Reports</i> , 2023, 6, .	0.6	3
1315	More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intolerance. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 4933-4938.	1.2	1
1316	Prognostic Impact of LAG-3 mRNA Expression in Early Breast Cancer. <i>Biomedicines</i> , 2022, 10, 2656.	1.4	3
1317	The prognostic significance of PD-L1 expression in patients with glioblastoma: A meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1318	Liquid Biopsy and Immuno-Oncology for Advanced Nonsmall Cell Lung Cancer. <i>Clinical Chemistry</i> , 2023, 69, 23-40.	1.5	8
1319	Cost of illness of stage IV non-small cell lung cancer (NSCLC) positive for programmed cell death ligand 1 (PD-L1) in the US. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 0, , 1-7.	0.7	0
1320	Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model. , 2022, 10, e005414.		18
1321	The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	0
1322	Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: A meta-analysis. <i>Journal of the National Cancer Institute</i> , 2023, 115, 29-42.	3.0	7

#	ARTICLE	IF	CITATIONS
1323	Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy. <i>International Immunopharmacology</i> , 2022, 113, 109365.	1.7	6
1324	RAS: Circuitry and therapeutic targeting. <i>Cellular Signalling</i> , 2023, 101, 110505.	1.7	1
1325	Development of models for predicting the objective response of immune checkpoint inhibitor therapy in patients with nonsmall-cell lung cancer. <i>Digital Medicine</i> , 2022, 8, 27.	0.1	0
1326	Harnessing the Tumor Microenvironment for Cancer Immunotherapy. , 2022, , 1-25.		1
1327	The Latest Information on Chemotherapy for Patients with Advanced Lung Cancer. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 2441-2448.	0.0	0
1329	Prognostic value of 18F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1330	Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	14
1331	Immunoterapia en cncer de pulmn metastsico. , 2022, 25, .		0
1332	The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1333	Clinical Implications and Molecular Characterization of Drebrin-Positive, Tumor-Infiltrating Exhausted T Cells in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13723.	1.8	0
1334	Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma. <i>Investigational New Drugs</i> , 2023, 41, 168-172.	1.2	1
1335	Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies. <i>Immunotherapy</i> , 0, , .	1.0	0
1336	How to manage KRAS G12C-mutated advanced non-small-cell lung cancer. , 0, 11, 1-11.		4
1337	Biomarkers in the management of lung cancer: changing the practice of thoracic oncology. <i>Clinical Chemistry and Laboratory Medicine</i> , 2023, 61, 906-920.	1.4	4
1339	Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1340	Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2023, 9, 40.	3.4	22
1341	Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis. <i>Annals of Oncology</i> , 2023, 34, 173-185.	0.6	8
1342	First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50). <i>Esophagus</i> , 2023, 20, 291-301.	1.0	13

#	ARTICLE	IF	CITATIONS
1343	Safety of Dueling NSCLC With Dual Agent Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2023, 18, 10-13.	0.5	0
1344	Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer. <i>International Immunopharmacology</i> , 2023, 114, 109589.	1.7	1
1345	Neptune, the Next Pluto?â€”Durvalumab and Tremelimumab Face Challenges in Entering theÂNSCLC Space. <i>Journal of Thoracic Oncology</i> , 2023, 18, 29-30.	0.5	0
1346	Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study. <i>Gynecologic Oncology</i> , 2023, 169, 64-69.	0.6	4
1347	Cancer Treatment Strategy by Fukushima Medical University Aims to Achieve. [Fukushima Igaku Zasshi] <i>Fukushima Medical Journal</i> , 2022, 72, 109-113.	0.1	0
1348	Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. <i>American Journal of Gastroenterology</i> , 2022, 117, 1917-1932.	0.2	4
1349	Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy. <i>Seminars in Immunopathology</i> , 0, , .	2.8	2
1350	Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
1351	Therapeutic Antibodies in Cancer Treatment in the UK. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14589.	1.8	1
1352	Fiveâ€year survival and clinical correlates among patients with advanced nonâ€small cell lung cancer, melanoma and renal cell carcinoma treated with immune checkâ€point inhibitors in Australian tertiary oncology centres. <i>Cancer Medicine</i> , 2023, 12, 6788-6801.	1.3	2
1353	Advances in the Lung Cancer Immunotherapy Approaches. <i>Vaccines</i> , 2022, 10, 1963.	2.1	6
1354	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. <i>Journal of Modern Oncology</i> , 2022, 24, 269-304.	0.1	2
1355	<i>SERPINB9</i> is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response. <i>Oncolimmunology</i> , 2022, 11, .	2.1	10
1356	Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1357	Cutting-Edge Developments in Oncology Research. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2022, 43, 451-457.	0.1	0
1358	Re-administration of immune checkpoint inhibitors for patients with non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 2170-2174.	1.3	0
1359	Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
1360	A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer. <i>European Radiology</i> , 2023, 33, 3918-3930.	2.3	6

#	ARTICLE	IF	CITATIONS
1361	Immune Checkpoint Inhibitor Therapy in Oncology. <i>JACC: CardioOncology</i> , 2022, 4, 579-597.	1.7	25
1362	Rational combinations of targeted cancer therapies: background, advances and challenges. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 213-234.	21.5	69
1363	Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5645-5653.	1.2	3
1365	Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden. <i>JAMA Oncology</i> , 2023, 9, 344.	3.4	13
1366	A Historical Misconception in Clinical Trials of Drugs for Cancer: Age Grouping. <i>Journal of Personalized Medicine</i> , 2022, 12, 1998.	1.1	0
1367	Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy. <i>Acta Biomaterialia</i> , 2023, 158, 698-707.	4.1	3
1368	The prospect of tumor microenvironment-modulating therapeutical strategies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
1369	Resistance to immune checkpoint inhibitors and the tumor microenvironment. <i>Experimental Dermatology</i> , 2023, 32, 240-249.	1.4	5
1370	Current status and challenges of immunotherapy in ALK rearranged NSCLC. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1371	MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors. <i>ESMO Open</i> , 2022, 7, 100646.	2.0	7
1372	Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seq. <i>British Journal of Cancer</i> , 2023, 128, 1148-1154.	2.9	2
1373	Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
1374	Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors. <i>Cancers</i> , 2022, 14, 6145.	1.7	10
1375	Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors. <i>PeerJ</i> , 0, 10, e14566.	0.9	1
1376	Immune-based combination therapy for esophageal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1377	Characterization of the high-affinity anti-CTLA-4 monoclonal antibody JS007 for immune checkpoint therapy of cancer. <i>MAbs</i> , 2023, 15, .	2.6	0
1378	Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1379	Clinical and technical insights of tumour mutational burden in non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 182, 103891.	2.0	6

#	ARTICLE	IF	CITATIONS
1380	Development and validation of a recursive partitioning analysisâ€‘based pretreatment decisionâ€‘making tool identifying ideal candidates for spine stereotactic body radiation therapy. <i>Cancer</i> , 0, , .	2.0	1
1381	Association between increased peripheral blood CD86-positive plasmacytoid dendritic cells and immune-related adverse events in patients with non-small cell lung cancer. <i>Global Health & Medicine</i> , 2022, 4, 301-308.	0.6	0
1383	A case of thoracic <sc><i>SMARCA4</i>-deficient</sc> undifferentiated tumor successfully treated with combination <sc>ipilimumabâ€‘Nivolumab</sc>. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.2	2
1386	Modelâ€‘based metaâ€‘analysis of nonâ€‘small cell lung cancer with standard of care <sc>PD</sc>-inhibitors and chemotherapy for early development decision making. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 1751-1763.	1.3	0
1387	Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis. <i>Lung Cancer</i> , 2023, 177, 11-20.	0.9	8
1388	Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1365-1379.	2.0	93
1389	Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer. <i>Cancers</i> , 2023, 15, 543.	1.7	8
1390	Genomic and immunogenomic analysis of three prognostic signature genes in LUAD. <i>BMC Bioinformatics</i> , 2023, 24, .	1.2	0
1391	Signaling pathways in brain tumors and therapeutic interventions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	13
1392	Thoracic imaging. , 2023, , 179-198.		0
1393	Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I. <i>Journal of the National Cancer Institute</i> , 2023, 115, 437-446.	3.0	3
1394	Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patients with Locally Advanced Nonâ€‘Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab. <i>JAMA Network Open</i> , 2023, 6, e2249591.	2.8	6
1395	Fundamentals to therapeutics: Epigenetic modulation of CD8+ T Cell exhaustion in the tumor microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	4
1396	At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 143-159.	12.5	29
1397	Increasing cure rates of solid tumors by immune checkpoint inhibitors. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	17
1398	Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. <i>Cancer Cell</i> , 2023, 41, 304-322.e7.	7.7	34
1399	Extracellular Vesicles Are Important Mediators That Regulate Tumor Lymph Node Metastasis via the Immune System. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1362.	1.8	3
1400	Optimizing molecular testing of lung cancer needle biopsy specimens: potential solutions from an interdisciplinary qualitative study. <i>Respiratory Research</i> , 2023, 24, .	1.4	2

#	ARTICLE	IF	CITATIONS
1401	Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives. <i>Biomarker Research</i> , 2023, 11, .	2.8	8
1402	<scp>Câ€PLAN</scp> index as a prognostic factor for patients with previously untreated advanced nonâ€small cell lung cancer who received combination immunotherapy: A multicenter retrospective study. <i>Thoracic Cancer</i> , 2023, 14, 636-642.	0.8	2
1403	Wnt/ β -Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers. <i>Biomedicines</i> , 2023, 11, 190.	1.4	9
1404	Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors. <i>Journal of the Endocrine Society</i> , 2023, 7, .	0.1	1
1405	Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer. <i>Journal of Cancer Policy</i> , 2023, 35, 100382.	0.6	1
1406	Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer. <i>Gene</i> , 2023, 857, 147177.	1.0	2
1407	Deciphering the Clinical Trials of Immunotherapy in Glioblastoma: What a Neuroradiologist Needs to Know. <i>Neurographics</i> , 2022, 12, 176-187.	0.0	1
1408	Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management. <i>Targeted Oncology</i> , 0, , .	1.7	1
1409	Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma. <i>European Journal of Internal Medicine</i> , 2023, 111, 37-46.	1.0	3
1410	DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort study. <i>Translational Lung Cancer Research</i> , 2022, 11, 2539-2566.	1.3	0
1411	Efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors in solid tumors based on clinical characteristics: a meta-analysis. <i>Immunotherapy</i> , 2023, 15, 189-207.	1.0	3
1413	Microsatellite instability assessment is instrumental for Predictive, Preventive and Personalised Medicine: status quo and outlook. <i>EPMA Journal</i> , 2023, 14, 143-165.	3.3	6
1414	First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes. <i>European Journal of Cancer</i> , 2023, 183, 174-187.	1.3	4
1415	Tumor immunology. , 2023, , 245-452.		0
1416	Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment?. <i>Cancers</i> , 2023, 15, 689.	1.7	5
1417	Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review. <i>Cancers</i> , 2023, 15, 682.	1.7	2
1418	Pulmonary Side Effects of Immunotherapy. , 2023, , 1-13.		0
1419	Costâ€effectiveness of firstâ€line immunotherapies for advanced nonâ€small cell lung cancer. <i>Cancer Medicine</i> , 0, , .	1.3	2

#	ARTICLE	IF	CITATIONS
1420	Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2023, 43, 713-724.	0.5	4
1421	Lung Immunotherapy in the Elderly with NSCLC – the Who, the What, and the When. , 2023, , .		0
1422	Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy. <i>BMC Cancer</i> , 2023, 23, .	1.1	6
1423	PD-L1: expression regulation. <i>Blood Science</i> , 2023, 5, 77-91.	0.4	5
1424	Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	3
1425	Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System. <i>Clinical Therapeutics</i> , 2023, 45, 151-159.	1.1	3
1426	NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer. <i>Lung Cancer</i> , 2023, 178, 87-95.	0.9	0
1427	Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
1428	Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis. <i>Open Medicine (Poland)</i> , 2023, 18, .	0.6	0
1429	Assessing the Relationship Between Liver Metastases and the Survival of Patients With Non-Small Cell Lung Cancer After Immune Checkpoint Inhibitors Treatment: A Systematic Review and Meta-Analysis. <i>Integrative Cancer Therapies</i> , 2023, 22, 153473542311645.	0.8	0
1430	Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment. , 2023, 11, e005509.		7
1431	IBIS: identify biomarker-based subgroups with a Bayesian enrichment design for targeted combination therapy. <i>BMC Medical Research Methodology</i> , 2023, 23, .	1.4	1
1432	Capillary Leak Syndrome With Pulmonary Edema Preceded by Organizing Pneumonia Caused by Combination Therapy With Nivolumab and Ipilimumab: A Case Report. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100491.	0.6	1
1433	Highlights into historical and current immune interventions for cancer. <i>International Immunopharmacology</i> , 2023, 117, 109882.	1.7	2
1434	Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients. <i>Investigational New Drugs</i> , 0, , .	1.2	0
1435	Updated Immunotherapy for Gastric Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 2636.	1.0	6
1436	Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives. <i>Pharmaceutics</i> , 2023, 15, 1143.	2.0	13
1437	Antibodies against endogenous retroviruses promote lung cancer immunotherapy. <i>Nature</i> , 2023, 616, 563-573.	13.7	59

#	ARTICLE	IF	CITATIONS
1438	Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. <i>International Immunopharmacology</i> , 2023, 117, 109881.	1.7	8
1439	Immunotherapy-based combinations in metastatic NSCLC. <i>Cancer Treatment Reviews</i> , 2023, 116, 102545.	3.4	6
1440	Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1/PD-L1 immune checkpoint inhibitors plus chemotherapy. <i>Cancer Treatment Reviews</i> , 2023, 116, 102542.	3.4	1
1441	Biomarkers of response to immunotherapy in early stage non-small cell lung cancer. <i>European Journal of Cancer</i> , 2023, 184, 179-196.	1.3	4
1442	Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives. <i>Lung Cancer</i> , 2023, 179, 107173.	0.9	7
1443	S-allylmercaptocysteine promotes anti-tumor immunity by suppressing PD-L1 expression. <i>Biomedicine and Pharmacotherapy</i> , 2023, 161, 114446.	2.5	0
1444	Identification and characterization of circular RNAs as novel putative biomarkers to predict anti-PD-1 monotherapy response in metastatic melanoma patients – Knowledge from two independent international studies. <i>Neoplasia</i> , 2023, 37, 100877.	2.3	3
1445	Extended Survival in Patients With Non-Small-Cell Lung Cancer Associated Brain Metastases in the Modern Era. <i>Neurosurgery</i> , 2023, 93, 50-59.	0.6	1
1446	First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. , 2023, 11, e006127.		14
1447	Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2023, 16, 233.	1.7	1
1448	Lung Cancer Resection after Immunochemotherapy Versus Chemotherapy in Oligometastatic Nonsmall Cell Lung Cancer. <i>Thoracic and Cardiovascular Surgeon</i> , 0, , .	0.4	3
1449	Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis. <i>Immunotherapy</i> , 2023, 15, 293-309.	1.0	2
1450	Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial. <i>Lung Cancer</i> , 2023, 178, 96-102.	0.9	1
1451	Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. <i>Nature Communications</i> , 2023, 14, .	5.8	18
1452	A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC. <i>Journal of Thoracic Oncology</i> , 2023, 18, 718-730.	0.5	8
1453	Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2023, 18, 731-743.	0.5	15
1454	Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity. <i>Cancer Science</i> , 2023, 114, 1859-1870.	1.7	6
1455	Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC. <i>Biomedicines</i> , 2023, 11, 508.	1.4	3

#	ARTICLE	IF	CITATIONS
1456	Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials. <i>Biomedicines</i> , 2023, 11, 528.	1.4	0
1457	Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers. <i>Current Oncology</i> , 2023, 30, 2366-2387.	0.9	5
1458	Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunotherapy for patients with potentially resectable non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
1460	Recently approved and emerging monoclonal antibody immune checkpoint inhibitors for the treatment of advanced non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2023, 23, 261-268.	1.4	1
1461	p53 mutation and deletion contribute to tumor immune evasion. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	2
1462	Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives. , 2023, 2, 65-78.		0
1463	VISTA expression and patient selection for immune-based anticancer therapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
1464	Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1465	Lung cancer immunotherapy: progress, pitfalls, and promises. <i>Molecular Cancer</i> , 2023, 22, .	7.9	104
1466	Quantitative, Spatially Defined Expression of Leukocyte-associated Immunoglobulin-like Receptor in Non-small Cell Lung Cancer. <i>Cancer Research Communications</i> , 2023, 3, 471-482.	0.7	0
1467	Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	2.0	0
1468	Predictive and Prognostic Implications of Circulating CX3CR1+ CD8+ T Cells in Non-small Cell Lung Cancer Patients Treated with Chemo-Immunotherapy. <i>Cancer Research Communications</i> , 2023, 3, 510-520.	0.7	2
1469	Liquid Biopsies in Lung Cancer. <i>Cancers</i> , 2023, 15, 1430.	1.7	7
1470	Chorioallantoic membrane assay revealed the role of TIPARP (2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible poly (ADP-ribose) polymerase) in lung adenocarcinoma-induced angiogenesis. <i>Cancer Cell International</i> , 2023, 23, .	1.8	3
1471	Targeting tumor microenvironment for non-small cell lung cancer immunotherapy. , 2023, , .		1
1472	MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2023, 18, 907-921.	0.5	7
1473	Immunotherapy of Osteosarcoma. , 2023, , 1-39.		0
1474	Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer. <i>Cancer</i> , 2023, 129, 1319-1350.	2.0	3

#	ARTICLE	IF	CITATIONS
1475	Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 1833.	1.0	4
1476	Characterization of a novel potency endpoint for the evaluation of immune checkpoint blockade in humanized mice. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1477	Cemiplimab as Second-Line Therapy for Patients with Recurrent Cervical Cancer: A United States-based Cost-effectiveness Analysis. <i>Advances in Therapy</i> , 2023, 40, 1838-1849.	1.3	6
1478	Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 184, 103954.	2.0	3
1479	Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
1481	Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1482	Roles and therapeutic implications of m6A modification in cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
1483	Comprehensive bioinformatic analysis constructs a CXCL model for predicting survival and immunotherapy effectiveness in ovarian cancer. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
1484	Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy. <i>JAMA Oncology</i> , 2023, 9, 627.	3.4	15
1485	Current Advances in Immune Checkpoint Therapy. , 0, , .		0
1486	Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China. <i>PharmacoEconomics - Open</i> , 2023, 7, 273-284.	0.9	1
1487	Occurrence and prognosis of lung cancer metastasis to major organs: a population-based study. <i>European Journal of Cancer Prevention</i> , 2023, 32, 246-253.	0.6	2
1488	Immune gene patterns and characterization of the tumor immune microenvironment associated with cancer immunotherapy efficacy. <i>Heliyon</i> , 2023, 9, e14450.	1.4	1
1489	Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment. , 0, 3, .		0
1490	Anti-PD-(L)1 therapy of non-small cell lung cancerâ€“A summary of clinical trials and current progresses. <i>Heliyon</i> , 2023, 9, e14566.	1.4	2
1491	Lung cancer management in low and middle-income countries - current challenges and potential solutions. <i>International Journal of Cancer Care and Delivery</i> , 2023, 3, .	0.0	0
1492	Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors. , 2023, 11, e005921.		6
1493	Tumor immune contexture predicts recurrence after prostatectomy and efficacy of androgen deprivation and immunotherapy in prostate cancer. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	0

#	ARTICLE	IF	CITATIONS
1494	Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions (CME article). International Journal of Cancer Care and Delivery, 2023, 3, .	0.0	0
1495	Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nature Medicine, 2023, 29, 593-604.	15.2	46
1496	Advancing neoadjuvant immunotherapy for lung cancer. Nature Medicine, 2023, 29, 533-534.	15.2	2
1498	Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications. Journal of Hematology and Oncology, 2023, 16, .	6.9	5
1499	Efficacy and toxicity profile of <sc>firstâ€line</sc> treatment for extensiveâ€stage small cell lung cancer: A Bayesian network <sc>metaâ€analysis</sc>. Cancer Medicine, 0, , .	1.3	2
1500	Patterns of Response to Immune Oncology Drugs: How Relevant Are They in SCCHN?. , 2023, , 217-228.		0
1501	Radiomics and Delta-Radiomics Signatures to Predict Response and Survival in Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Cancers, 2023, 15, 1968.	1.7	7
1502	Neoadjuvant immunotherapy in resectable non-small-cell lung cancer. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311637.	1.4	4
1503	Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial. Journal of Thoracic Oncology, 2023, 18, 755-768.	0.5	13
1504	Comparative oncology: overcoming human cancer through companion animal studies. Experimental and Molecular Medicine, 2023, 55, 725-734.	3.2	5
1505	Randomized Clinical Trials: Pitfalls in Design, Analysis, Presentation, and Interpretation. Medical Radiology, 2023, , .	0.0	0
1506	The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors. Antibodies, 2023, 12, 27.	1.2	1
1507	Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies. Frontiers in Immunology, 0, 14, .	2.2	8
1508	Immune Responses to Solid Tumors and Immune Checkpoint Therapy. , 2023, , 1028-1041.		0
1509	Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nature Genetics, 2023, 55, 807-819.	9.4	18
1510	Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. Advances in Anatomic Pathology, 2023, 30, 174-194.	2.4	0
1512	Palliative Care in the New Era of Lung Cancer Treatment. Journal of Hospice and Palliative Nursing, 0, Publish Ahead of Print, .	0.5	0
1513	The Significance of SPP1 in Lung Cancers and Its Impact as a Marker for Protumor Tumor-Associated Macrophages. Cancers, 2023, 15, 2250.	1.7	17

#	ARTICLE	IF	CITATIONS
1514	The efficacy and safety of anti-PD-1/PD-L1 in treatment of glioma: a single-arm meta-analysis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
1515	Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level. <i>Annals of Oncology</i> , 2023, 34, 327-332.	0.6	0
1516	The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer. <i>Cancers</i> , 2023, 15, 2319.	1.7	1
1517	Immunotherapy in Lung Cancer: Current Landscape and Analysis of Biomarkers. <i>World Journal of Cancer Research</i> , 2023, 13, 37-43.	0.1	0
1518	Identifying optimal first-line immune checkpoint inhibitors based regimens for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis. <i>PLoS ONE</i> , 2023, 18, e0283719.	1.1	1
1520	Extended Application of Genomic Selection to Screen Multi-Omics Data for the Development of Novel Pyroptosis-Immune Signatures and Predicting Immunotherapy of Glioma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
1521	Effects of Auricular Acupressure on Symptom Burden and Quality of Life in Patients With Advanced Lung Cancer Treated With Immunotherapy Based on the Midnight-noon Ebb-flow Theory: A Randomized Controlled Trial. <i>Cancer Care Research Online</i> , 2023, 3, e040.	0.1	0
1523	Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
1524	Early Changes of Serum Interleukin 14 \pm Levels Predicts the Response to Anti-PD-1 Therapy in Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2023, 17, 117955492311633.	0.6	0
1525	Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances. <i>Pathology Research and Practice</i> , 2023, 246, 154470.	1.0	0
1546	Immunotherapy and Cancer: The Pharmacistsâ€™ Perspective. , 2023, , 1-34.		0
1559	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
1641	Advancement and Applications of Nanotherapy for Cancer Immune Microenvironment. <i>Current Medical Science</i> , 2023, 43, 631-646.	0.7	0
1652	Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	34
1705	Immunotherapy for Non-small Cell Lung Cancer. , 2023, , 1-25.		0
1713	First-line therapy. , 2024, , 175-194.		0
1715	Treatment of Stage IV Non-small Cell Lung Cancer. <i>Respiratory Medicine</i> , 2023, , 165-186.	0.1	0
1729	Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases. <i>British Journal of Cancer</i> , 0, , .	2.9	0

#	ARTICLE	IF	CITATIONS
1746	Immunoradiotherapy for NSCLC: mechanisms, clinical outcomes, and future directions. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	0
1761	Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. <i>Nature Reviews Immunology</i> , 0, , .	10.6	2
1773	Lung Cancer in Elderly: Patient-Centered Approach for Optimal Delivery of Care. , 2024, , 1-17.		0
1788	Immune Checkpoint Inhibition. , 2024, , 1-91.		0
1812	Cancer immunotherapy-associated endocrine complications and treatment strategies. , 2024, , 199-221.		0
1827	Dendritic cells as orchestrators of anticancer immunity and immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2024, 21, 257-277.	12.5	1
1832	Lung Cancer in Elderly: Patient-Centered Approach for Optimal Delivery of Care. , 2024, , 869-884.		0
1838	Importance of targeting various cell signaling pathways in solid cancers. <i>International Review of Cell and Molecular Biology</i> , 2024, , .	1.6	0